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Abstract 
Transactive response DNA binding protein, 43 kDa (TDP-43) is 416-residue RNA 
processing and transport protein, observed in insoluble cytoplasmic aggregates 
within affected neurons in neurodegenerative diseases.  TDP-43 has three 
domains: the N-terminal (N), RNA-binding (R) and unstructured C-terminal 
domains (G).  Unstructured domains often form intramolecular interactions 
regulating other domains; our goal was to determine if such an interaction occurs 
in TDP-43.  In Far Western blots, tagged NR was observed to bind to G. A ten 
residue C-terminal truncation of G virtually abolished binding and introduction of 
phosphomimetics at Ser409/Ser410 also reduced binding.  Sedimentation velocity 
ultracentrifugation with tagged NR and G also revealed interaction, observed by a 
shift in sedimentation coefficients when compared to those of the individual 
polypeptides.  In vivo colocalization studies confirmed a cellular interaction 
between fluorescently labeled NR and G.  This interaction has potential 
implications for the regulation of TDP-43 and the mechanism of generation of 
aggregative forms. 
 
 
Keywords: TDP-43, intrinsically disordered protein, analytical ultracentrifugation, 
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Chapter 1: Introduction 
In devastating neurodegenerative diseases including amyotrophic lateral 
sclerosis (ALS) and frontotemporal dementia (FTD), transactive response DNA 
binding protein 43 kDa (TDP-43) has been identified as a hallmark component of 
pathological intracellular inclusions found in patients (1–3).  These TDP-43 positive 
inclusions are typically found in both upper and lower motor neurons in the spinal 
cord, cortex and hippocampus of affected individuals (4–6).  Initially discovered as 
bound to transactive response sequences in HIV DNA (7), TDP-43 has since been 
implicated in multiple other diseases including cystic fibrosis (8, 9), Alzheimer’s 
disease (10, 11), Parkinson’s disease (10) and Alexander’s disease (12).  
Incomplete characterization of the structure and function of TDP-43 has thus far 
prevented a thorough understanding of its roles in healthy and disease states. 
TDP-43 is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP)  
family of proteins (7).  hnRNPs have a characteristic RNA-binding domain, 
comprised of highly structured nucleotide binding motifs called RNA recognition 
motifs (RRMs), followed by an unstructured, glycine-rich C-terminal domain (8, 13–
15).  The domain organization of TDP-43 is closely related to that of the hnRNP 
A/B type, as demonstrated in the sequence alignment in Figure 1A&B (14, 15).  In 
addition to the RNA-binding and unstructured domains, TDP-43 has a structured 
domain N-terminal to the RNA-binding domain, called the N-terminal domain, as 
outlined in Figure 1A. 
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Figure 1. Sequence illustration of the hnRNP family.  A) Schematic diagram of 
TDP-43 domain boundaries.  Each domain is highlighted and named.  The colours 
will be carried throughout this work to represent each domain in further diagrams. 
NLS-Nuclear localization signal; NES-Nuclear export signal; RRM-RNA 
recognition motif.  B) Sequence alignment of two hnRNPs, A1 and A2/B1, and the 
414 residue TDP-43.  The two RRM domains are highlighted in dark and light 
green.  The glycine residues are coloured blue. 
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The human TARDBP gene is located on chromosome 1 at 1p36.21 and 
contains 6 exons that can be alternatively spliced, encoding at least five TDP-43 
variants in human cells (13).  Orthologous TDP-43 genes have been identified in 
other eukaryotes including mouse, Caenorhabditis elegans (C. elegans) and 
Drosophila melanogaster (13).  Human TDP-43 has high sequence identity with its 
orthologous proteins in Drosophila (59%) and C. elegans (38%) (16).  The greatest 
sequence variation in orthologous TDP-43 proteins is in the C-terminal domain 
which may cause variation in the functions of TDP-43 across species such as 
RNA-binding but this is still not well understood (13). The most commonly reported 
isoform of TDP-43 is 414 amino acids in length and it is recorded as isoform 1 by 
the UniProt database (17).  A second isoform of 416 amino acids was the primary 
species isolated from healthy human brain (18) by this lab and it is the variant used 
throughout this work. 
TDP-43 is a primarily nuclear protein and is involved in many aspects of 
RNA processing including transcription, stability, splicing and transport.  Through 
both nuclear export (NES) and localization signals (NLS) (Figure 1A), TDP-43 
moves between the nucleus and the cytoplasm (19).  The RNA-binding domain of 
TDP-43 binds (UG)n-rich sequences in its target mRNA species; these sequences 
are most commonly located in the 3’UTR or at splicing junctions (8, 20).  Similar to 
other hnRNPs, the C-terminal domain of TDP-43 has been demonstrated to bind 
with many other proteins and has multiple sites for post-translational modification 
(21).  The C-terminal domain is intrinsically disordered and may also modulate 
function through intramolecular interactions.  Many studies have revealed the 
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intrinsic aggregative properties of TDP-43 through both in vitro and in vivo methods 
that replicate the TDP-43 positive inclusions found in neurodegenerative diseases 
(22–28).  These inclusions contain hyperphosphorylated and polyubiquitinated, 
full-length and C-terminal fragments of TDP-43, as well as RNA species and 
proteins found in stress granules (19). 
Whether some degree of self-interaction/aggregation is functional or strictly 
pathological is not known.  If self-interaction is not functionally relevant, then 
pathological conditions may arise from natural protein aggregation due to excess 
protein in the cell and the aggregation prone nature of the C-terminal domain.  
However, if self-interaction is functional for increasing RNA stability or transport, 
then it would have to be tightly regulated to avoid excessive interactions which may 
lead to aggregation.  Developing a more basic understanding of TDP-43 is 
necessary for understanding how TDP-43 correctly forms protein interactions and 
whether mutations or modifications to TDP-43 that are associated with disease-
related aggregation alter this process.  Our overall hypothesis is that the domains 
of TDP-43 do participate in intramolecular interactions. 
 
1.1 Cellular Functions of TDP-43 
TDP-43 was initially described as repressing the expression of HIV genes 
through binding the TAR DNA sequence and blocking the transcription factors that 
would initiate expression of HIV-1 genes (7).  Since then, TDP-43 has been shown 
to be associated with splicing regulation, mRNA stability, transcriptional regulation, 
microRNA processing and the cellular stress response (Figure 2) (reviewed in 29).  
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When TDP-43 becomes aggregated in disease states, it is plausible to assume 
that normal function is reduced or lost.  Gaining further understanding of the normal 
functions of TDP-43 is critical to discovering the cellular basis of TDP-43 
aggregation that leads to toxicity because very little is known about the regulation 
of cell localization or of protein interactions in a functionally normal state. 
 
1.1.1 TDP-43 localization—In a global analysis of the TDP-43 interactome, two 
protein networks were strongly represented in the interactions with TDP-43: 
Nuclear/transcriptional proteins and cytoplasmic/translational proteins (30).  In the 
first group, interacting proteins include transcription factors, hnRNPs, splicing 
factors and RNA transport proteins.  This does not come as a surprise since TDP-
43 has already been observed to play a critical role in many of these nuclear RNA 
processes, and the experimental protocol lacked ribonuclease.  The discovery of 
interactions with the cytoplasmic translation machinery and ribosomal subunits 
suggests TDP-43 stays associated with its target mRNA and continues to have a 
role outside the nucleus (30).  With roles in different compartments of the cell, the 
NLS and NES within TDP-43 are necessary for TDP-43 distribution within the cell 
(31).   Perturbing either of these signals by mutations causes TDP-43 to aggregate 
in the nucleus or cytoplasm of primary neurons, sequestering endogenous TDP-
43 with it (31).  If mutations to the localization signals can have such a strong effect 
on TDP-43, control over cellular location must be critical to its physiological 
function. 
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Figure 2. Schematic diagram of the various functions of TDP-43 within a cell.  TDP-
43 is primarily found within the nucleus (shaded area), where it participates in 
many functions in mRNA processing including mRNA stability, splicing and miRNA 
processing.  TDP-43 can also be transported from the nucleus to the cytoplasm 
where it is involved in further processes including miRNA processing and mRNA 
translation.  TDP-43 is also a component of stress granules.  After its cytoplasmic 
function is complete, TDP-43 can then be transported back into the nucleus.  
Shapes not corresponding to TDP-43 are protein placeholders to illustrate the 
functions described by this figure.  The functions illustrated include the hypothesis 
of this thesis. 
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1.1.2 Splicing—A well-characterized function of TDP-43 is its effect on splicing of 
the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA (8).  This 
is mediated by TDP-43 binding to a UG repeat rich region at the intron 8/exon 9 
junction of the CFTR gene, where TDP-43 binding inhibits splicing.  When TDP-43 
binds at a junction, the spliceosome is blocked from acting on this junction and 
skips to the next intron, effectively removing exon 9 and producing a non-functional 
CFTR protein (8).  Deletion of the TDP-43 C-terminal domain prevented both 
human and Drosophila TDP-43 from properly interacting with, and splicing, the 
target CFTR mRNA (13).  C. elegans TDP-43 does not have the same disordered 
C-terminal domain and also does not participate in splicing (13).  Therefore, the C-
terminal domain of TDP-43 is likely important for interaction with the splicing 
machinery (8, 13).  TDP-43 has also been found to have an effect on splicing of 
mRNA for other genes including BRCA1, ETF1 and RXRG (32).  The ability of 
TDP-43 to interact with hnRNPs and other nuclear factors is required for proper 
splicing function (33, 34).  Disruption of interactions, including induction of 
cytoplasmic aggregates, removes the functional pool of nuclear TDP-43 and 
reduces the ability of TDP-43 to aid in splicing (35). 
 
1.1.3 mRNA stability—Along with splicing, TDP-43 has a role in mRNA stability.  
Human neurofilament (hNEFL) mRNA was co-immunoprecipitated with TDP-43 
(18).  The binding region was mapped to the 3’UTR of hNEFL, where proper folding 
of the mRNA creates a (UG)6 sequence for TDP-43 to bind (36).  Binding and 
stabilization by TDP-43 is necessary for proper hNEFL expression through 
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interaction with other cellular RNA processing machinery (18).  TDP-43 also binds 
with HDAC6 mRNA and is necessary for maintaining HDAC6 mRNA and protein 
levels in vivo (37).  Knockdown of TDP-43 decreased the amount of HDAC6 in 
HEK293 and SH-SY5Y cells and in Drosophila (37).  Knockdown of TDP-43 also 
induced instability of Atg7 mRNA, which is the transcript for a protein critical to 
autophagy (38).  If autophagy is compromised, aggregates of TDP-43 would not 
be efficiently cleared from cells, inducing further toxicity (38).  Conversely, TDP-43 
knockdown increased the mRNA and protein levels of Cdk6 (39).  CDK6 mRNA, 
like hNEFL mRNA, has TDP-43 recognition sequences in the 3’UTR but the 
opposite effect of TDP-43 expression on Cdk6 protein expression indicated a more 
complicated role for TDP-43.  Perhaps the most important known mRNA 
interaction of TDP-43 is with the TARDBP transcript itself; TDP-43 negatively 
regulates its own expression by binding a recognition sequence in the 3’UTR and 
destabilizing the TARDBP mRNA (40).  This negative feedback loop suggests the 
importance of closely regulating TDP-43 levels so that upon TDP-43 binding with 
a mRNA substrate, the subsequent actions are correct for the fate of the bound 
mRNA species. 
 
1.1.4 microRNA processing—In a TDP-43 knockdown model in Hep-3B cells, 
many miRNAs were discovered to be significantly decreased (41).  TDP-43 
interaction with the Drosha and Dicer complexes is critical in miRNA biogenesis 
(42).  Immunoprecipitation with a FLAG antibody (anti-FLAG) pulled down a FLAG-
tagged Drosha and its complex where a direct interaction between Drosha and 
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TDP-43 was observed, regardless of the presence of RNA, through TDP-43’s C-
terminal domain (42).  A similar direct interaction was found for cytoplasmic TDP-
43 and FLAG-Dicer (42).  In the reciprocal experiment, anti-FLAG pulled down 
FLAG-TDP-43 with Drosha or Dicer (42).  Deletion of the C-terminal domain 
prevented interaction with the splicing machinery (42).  When TDP-43 was 
knocked down in Neuro2A cells, miRNA production critical for neurite outgrowth 
was reduced (42). 
 
1.1.5 Cellular stress response—Another area of increasing interest is a role for 
TDP-43 in the cellular stress response (43, 44).  After exposure to various 
stressors including sodium arsenite, thapsigargin and heat shock, TDP-43 and 
hnRNP A2 were sequestered to stress granules (44).  In TDP-43 depleted cells, 
stress granules took longer to form and were smaller in size (44).  In addition to 
granule formation, loss of TDP-43 also reduced expression of the key stress 
response proteins, TIA-1 and G3BP (44).  When the C-terminal domain of TDP-43 
was deleted, stress granules failed to form after exposure to sorbitol (43).  Another 
study has shown that the family of FOXO transcription factors are activated by 
TDP-43 after exposure to stress (45).  The stress response triggers translocation 
of TDP-43 to the cytoplasm, where it relieves inhibition of FOXOs by 14-3-3.  TDP-
43 competitively interacted with 14-3-3, which allowed the FOXO proteins to return 
to the nucleus and as a result expression of stress response proteins occurred 
(45).  TDP-43 and 14-3-3 then associated with stress granules to sequester 
unneeded mRNAs from translation (45).  Additionally, TDP-43 may be involved in 
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disrupting endoplasmic reticulum/mitochondria contacts through dissociation of 
VAPB and PTPIP51, following activation of GSK-3β (46).  Loss of the interaction 
between VAPB and PTPIP51 causes an imbalance in Ca2+ homeostasis and 
activation of a stress response (46). 
 
1.2 Domain Structure and Function 
 As previously stated, TDP-43 has three domains: the N-terminal, RNA-binding 
and C-terminal domains.  Figure 3 shows the amino acid sequence of TDP-43 and 
highlights the important regions and residues for structure and function as currently 
known. 
 
1.2.1 N-terminal domain—The N-terminal domain (N) is classically defined as the 
first 101 amino acids of TDP-43, and includes a putative NLS at position 82-98 (47, 
48).  The NLS is critical to TDP-43 function as while TDP-43 is primarily found in 
the nucleus, it shuttles to and from the cytoplasm in response to cellular stress or 
injury (47).  Another interesting region within the N-terminal domain is a highly 
conserved, highly acidic region (residues 9-23) but the exact function of this region 
is not known  (8, 9).  Online software such as PredictProtein 
(www.predictprotein.org) predicts the formation of β–sheets and α-helices within 
the N-terminal domain of TDP-43 (49). 
Recent nuclear magnetic resonance (NMR) and circular dichroism (CD) 
studies on the N-terminal domain indicate the presence of secondary structures as 
predicted (48, 50, 51).  The NMR analysis on a polypeptide of TDP-43 residues 1-
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105 indicated the presence of a structured domain with some helices but the actual 
structure formed could not be determined, as the workable concentration was too 
low, however there was likely some presence of oligomers (50).  CD analysis on 
the same polypeptide indicated the presence of both β–strands and α-helices (50).  
Similar studies on residues 1-102 of the N-terminal domain suggested the 
existence of two conformations in equilibrium, a folded and an unfolded form, that 
were not evident in a construct consisting only of residues 1-80 (51).  The structure 
was solved by NMR and the folded form was suggested to have a ubiquitin-like 
fold (51).  The N-terminal domain also did not significantly contribute to 
oligonucleotide binding (50). 
Co-immunoprecipitation of differentially tagged TDP-43 proteins revealed 
the ability of TDP-43 to form dimers, where the N-terminus was necessary for 
dimerization (48, 52, 53).  Further investigation through deletion mutants and in 
vivo crosslinking showed the first 10 amino acids of the N-terminal domain to be 
essential for dimer formation (48).  In silico modeling also demonstrated that these 
amino acids may form a loop structure that positions the rest of the TDP-43 
molecule for correct interaction with another TDP-43 molecule (48).  
 
1.2.2 RNA-binding domain—The RNA-binding domain (residues 102-262) 
consists of two highly conserved RRMs: RRM1 and RRM2.  The sequences are 
highlighted in green in Figure 3 and the solution structure is shown in Figure 4.  
RRMs are common in many well characterized nucleotide binding proteins, 
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Figure 3.  Amino acid sequence of the 416 residue TDP-43 isoform.  Highlighted 
are some important sequences and residues that are mentioned throughout this 
work.  The N-terminal domain (yellow) also contains the nuclear localization signal 
(NLS) (pink).  The RNA-binding domain (green) is made up of two RNA recognition 
motifs (RRMs) in dark green, RRM1, and light green, RRM2.  Within each RRM, 
are two highly conserved ribonucleoprotein sequences (RNP-1 and RNP-2) that 
contain the critical residues for RNA-binding (highlighted in green).  The C-terminal 
domain (blue) is glycine rich (highlighted in blue) and contains the hydrophobic 
patch and the glutamine/asparagine rich (Gln/Asn-rich) region. 
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including hnRNPs, Sxl and PABP (54).  Structurally, RRMs fold with a 4-strand β-
sheet, connected by 3 α-helices Figure 4B (54).  Tandem RRMs, as found in TDP-
43, typically increase the binding affinity of the protein to mRNA (54).  RRM2 also 
contains the putative NES (residues 239-250) (47).  The two RRMs of TDP-43 
appear to have different stabilities when exposed to denaturing conditions (55).  
Structural studies using CD revealed an intermediate state in the melting of RRM2 
that was not evident in the CD spectrum of RRM1 during chemical denaturation.  
Most importantly, tethering the two RRMs with the natural linker sequence 
increased stability compared to RRM1 alone (55).  When RRM1 and RRM2 are 
tethered, the hydrophobic residue clusters in RRM2 make contacts with RRM1, 
contributing to stability (55).  Disrupting the native structure of RRM2 by a cleavage 
N-terminal to Arg208 increased the population of the intermediate state and this 
mutant had a higher affinity for RNA than full RRM2 (55).  It is unclear whether the 
intermediate state is functionally relevant.   
In 2009, the first crystal structure of TDP-43 was solved, with RRM2 only 
(residues 192-265) in complex with ssDNA (56).  Since then, the solution NMR 
structure of the full RNA-binding domain, both RRM1 and RRM2 bound to an RNA 
species (5’- GUGUGAAUGAAU-3’), was solved (Figure 4) (57).  This new structure 
was critical for gaining a better understanding of the RNA sequence specificity of 
TDP-43.  The RNA molecule was bound across the β-sheet surfaces of both RRMs 
with the guanine in position 5 inserted between the two domains (Figure 4A).  This 
base made contacts with both RRMs, appearing to hold them in a rigid structure.   
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Figure 4. Solution NMR structure of the RNA-binding domain (residues 96-267) of 
TDP-43 (PDB: 4BS2). A) Full structure of this domain bound to an RNA species, 
sequence 5’-GUGUGAAUGAAU-3’: RRM1 is displayed in darker green on the left, 
bound with the 5’ end of the RNA, RRM2 is in light green.  The NES is indicated 
by the pink region within RRM2.  B) A single RRM and the significant secondary 
structures.  The α-helices and β-sheets are colour coded in the corresponding 
sequences at the bottom. C) Close up of RRM1 and the residues that make base-
specific contacts with the RNA species: I107 and F149 (yellow).  D) Close up of 
RRM2 and the residues that make base-specific contacts with the RNA species: 
F194 and F231 (yellow).  This figure was constructed with Pymol. 
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Only bases G1, G3, U4, G5, U8 and G9 made base-specific contacts with the 
RRMs.  The 5’ nucleotide base bound with RRM1, while the downstream 
nucleotides bound to RRM2; this is opposite to other proteins with tandem RRMs 
where the 5’ base binds with the second RRM in the sequence (57).   
Within each RRM of TDP-43, there are two conserved sequences called 
ribonucleoprotein sequences (RNP-1 and RNP-2).  These have consensus 
sequences of approximately eight residues that are hydrophobic or positively 
charged to interact with nucleotides: KGFGFVRF for RNP-1 and LIVLGLPW for 
RNP-2 (29, 58).  RNP-1 and RNP-2 are located in the β-sheet, creating a binding 
surface for ssDNA or RNA.  Figure 4B and C highlights these residues and the 
direct contacts made with an RNA oligo, as observed in the NMR structure.  In 
RRM1, Ile109 and Phe149 make direct contacts with bases U4 and G5, 
respectively.  In RRM2, Phe194 and Phe231 make contacts with U8 and G9, 
respectively.  These contacts appear like base-stacking interactions that precisely 
position the RNA and likely contribute to specificity (57).  Introducing the mutations 
F147L and F149L to TDP-43 completely abolished binding with both (TG)6 and 
(UG)6 species (20, 59).  Based on the NMR structure, the precise UG-rich 
consensus sequence for binding to TDP-43 was suggested to be 5’-
GNGUGNNUGN-3’ (16,17).  Finally, RRM1 was crystallized alone with (TG)n 
ssDNA (59).  The ssDNA bound to the β-sheet surface with the same orientation 
as observed in the NMR structure, where the nucleotides at G2, G4, C5 and G6 
make direct contacts with the protein (59).  This finding established a similar 
consensus sequence for ssDNA binding as with RNA.   
17 
 
 
Following the discovery of RRMs in TDP-43, oligonucleotide binding assays 
were conducted to determine the binding specificity of TDP-43.  TDP-43 is capable 
of binding both (UG)n and (TG)n repeats in RNA and ssDNA, respectively (20, 56).  
Binding was observed with sequences of 3-12 repeats, where affinity increased as 
the oligonucleotide length increased.  Using a truncated TDP-43 with only the 
RNA-binding domain, the Kd of (UG)n binding decreased from increasing 
oligonucleotide length from 3,060 nM (n=3) to 2.79 nM (n=8) (56).  TDP-43 did not 
efficiently bind with non-(UG)n sequences that were tested (56).  Deletion of RRM1, 
but not deletion of RRM2, abolished nucleotide binding and RRM1 alone bound 
(UG)n/(TG)n repeats with a much higher affinity than RRM2 (20).  Surprisingly, 
RRM2 bound more strongly with smaller oligonucleotides than larger, opposite to 
what was measured with RRM1 (56).  In a crystal structure of RRM2 alone, dimers 
were observed but it is not clear whether this dimerization interface is biologically 
relevant or a crystal contact only (56).  Crosslinking immunoprecipitation was used 
to find the binding sequences within the 3’UTR of TARDBP mRNA for a construct 
of the RNA-binding domain only (60).  Of the two identified oligonucleotides, the 
longer sequence bound with higher affinity than the shorter, Kd = 112 nM and 262 
nM, respectively (60).  In addition, comparable affinities were measured for a 
similar construct with the residues Phe229 and Phe231 of RRM2 mutated to 
leucines.  The Phe residues of RRM2 were not as critical to RNA binding, unlike 
the similar residues in RRM1 (60). 
It appears that regions with a UG-rich sequence provide more favourable 
binding conditions for TDP-43.  Protein binding is dynamic, therefore more 
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available binding sequences allow for regulation by TDP-43 to be maintained for a 
longer time (60).  In addition, correct binding by RRM1 is most important for 
sequence recognition where as RRM2 merely contributes to binding. 
 
1.2.3 C-terminal domain—Perhaps the most interesting domain of TDP-43 is the 
C-terminal domain, consisting of residues 263-414.  This domain is glycine-rich 
(25%) and predicted to be intrinsically disordered by the online structure prediction 
software, DISOPRED (http://bioinf.cs.ucl.ac.uk/psipred/?disopred=1) (61, 62).  
Figure 5 shows the output from DISOPRED, where a probability of 1 is indicative 
of a likely region of disorder.  The C-terminal domain, indicated by blue, is largely 
disordered.  The region of predicted order within the C-terminal domain has been 
labelled a “hydrophobic patch” (residues 318-343; HP) and through solution NMR 
studies of a peptide encompassing resides 311-360, was determined to form a 
helix-turn-helix motif in solution (63).  There is also a region rich in glutamine and 
asparagine (residues 344-365; Q/N) that has been implicated in nucleating TDP-
43 aggregation (24, 64).  These two regions are labelled in Figure 5. 
 The C-terminal domain has been observed as a key part of TDP-43 protein 
interactions.  TDP-43 was first observed to interact with hnRNP A1, hnRNP A2/B1 
and hnRNP C1/C2, while deletion of the C-terminal domain ablated the interaction 
(33).  The region of interaction was more precisely mapped to residues 321-366 
by truncating TDP-43 and measuring interaction with hnRNP A2 (65).  Introducing 
a synthetic peptide corresponding to this region was even capable of disrupting 
TDP-43/hnRNP A2 interaction.  This 45 residue region is highly conserved in 
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Figure 5. Disorder prediction and sequence outline of TDP-43 structure.  A) The 
disorder prediction for the full TDP-43 sequence shows a high level of disorder 
within the C-terminal domain (blue).  Calculated using DISOPRED software.  Two 
regions of the C-terminal domain are indicated: the hydrophobic patch (HP), 
residues 318-343, and the Gln/Asn-rich region (Q/N), residues 344-365. 
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homologous TDP-43 proteins across species, demonstrating an importance for 
interaction with hnRNPs (65).  Upon closer inspection, the C-terminal domain has 
a particularly glutamine/asparagine (Gln/Asn)–rich region (residues 344-365) 
located within the protein interacting region (24).  Polyglutamine or Gln/Asn-rich 
regions are highly aggregation-prone and often nucleate toxic protein aggregates 
(66).  C-terminal fragments of TDP-43 containing this region form insoluble 
inclusions in cells and even sequester endogenous TDP-43 in cells (24).  The 
expression of 12 tandem repeats of residues 342-366 could form aggregates within 
cells and these aggregates could sequester endogenous TDP-43 (64). 
In addition to the Gln/Asn-rich region, the aforementioned “hydrophobic 
patch” was also found to contribute to TDP-43 aggregation (63).  A polypeptide of 
TDP-43 residues 311-360, which contained the hydrophobic patch, appeared to 
form some α-helical structure after analysis by CD and NMR spectroscopy (63).  
After incubation, the percentage of α-helical structure decreased while the β-sheet 
content increased, consistent with observations in other polyglutamine aggregate 
proteins (63, 67).  Deletion of the hydrophobic patch decreased the amount of 
aggregation observed in cells (63).  The combination of the hydrophobic patch and 
the Gln/Asn-rich region was named the “amyloidogenic core” for its resemblance 
to other β-amyloid aggregating proteins where α-helix to β-sheet structural 
transformation propagates aggregation (63, 68). 
 
1.2.4 TDP-43 interactions and aggregation—TDP-43 protein is found aggregated 
in multiple diseases (2).  The aggregates often contain C-terminal fragments of 
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TDP-43, cleaved at Arg208, which is located in the first helix of RRM2 (2, 22).  
Overexpression of this fragment in cells triggered aggregation similar to that found 
in patient cases (22) while deletion of the C-terminal domain prevented it (69).  
Over 40 TDP-43 mutations, the majority of which are in the C-terminal domain 
(Figure 6), have been associated with disease (70).  The different mutations had 
varying effects on aggregation by stabilizing or destabilizing structures that were 
considered relevant for aggregate formation (68). 
While C-terminal mutations are not necessary for toxic inclusions to form, it 
is clear that the C-terminal domain is critical for normal structure and function of 
TDP-43.  Its intrinsic tendency for protein interaction may lead to small oligomers 
that are biologically normal and pathogenic aggregation may only be due to 
dysregulation of this tendency.  This is why a more basic understanding of the 
normal functions of TDP-43 will be critical for understanding its role in disease. 
 
1.3 TDP-43 in Disease Pathology 
As previously mentioned, TDP-43 was first discovered bound to TAR 
sequences of HIV-1 DNA,  repressing transcription of these genes (7).  Since then, 
the active involvement of TDP-43 in preventing HIV-1 replication in immune cells 
has been refuted (71) but evidence for TDP-43 involvement in the pathogenesis of 
other diseases has arisen. 
In cystic fibrosis (CF), TDP-43 binds at the 3’ splice site of exon 9 in CFTR 
mRNA, excluding exon 9 from the mature mRNA.  The resulting protein is non-
functional (3, 57).  This splice site has a (UG)m(U)n region in which polymorphisms  
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Figure 6. Mutations in TDP-43 in neurodegenerative diseases.  A) Highlights the 
full sequence of TDP-43 where the identified mutations (  ) are largely concentrated 
to the C-terminal domain.  One mutation, D169G is in RRM1.  B) Mutations 
currently associated with neurodegenerative diseases in the C-terminal domain 
(70). 
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introduce more or less favourable sites for regulatory factors to bind.  Knockdown 
of TDP-43 in culture and patient cells, with or without unfavourable sequences, 
reduced the amount of misspliced CFTR.  This finding suggests a critical role of 
TDP-43 in the regulation of splicing and a possible therapeutic target for patients 
with CF (72). 
TDP-43 is also found in cellular inclusions in neurodegenerative diseases 
such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) 
(26, 53).  These cytoplasmic inclusions contain TDP-43 that is often hyper-
phosphorylated, ubiquitinated and N-terminally cleaved (1–3).  TDP-43 cleavage, 
similar to that observed in patients, was induced in vitro after exposure to caspase-
3 and caspase-7 (73, 74).  There are three predicted cleavage sites within TDP-
43 for caspase cleavage at 10DEND, 86DETD, 216DVMD with predicted cleavage 
products of 42, 35 and 25 kDa, respectively (73).  Two fragments, 25-kDa and 35-
kDa (73), of TDP-43 have been identified in patients with neurodegenerative 
diseases and similar polypeptides were observed experimentally to recapitulate 
the pathological aggregates observed in patients (26, 53).  Caspase-3 and 
caspase-7 mediated cleavage was also induced in multiple cells lines including 
HeLa (cervical cancer) and THP-1 (acute monocytic leukemia) after a treatment to 
reduce the Ca2+ availability in vivo (74). 
Further investigation into TDP-43 involvement in neurodegenerative 
diseases revealed cleaved and phosphorylated TDP-43 inclusions in the brains of 
Alzheimer’s patients who developed cognitive impairment and patients with Lewy 
body dementia (11, 75).  With over 40 TDP-43 mutations identified to date in 
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patients with neurodegenerative disease (Figure 6) (76–78), it is becoming evident 
that aggregation of TDP-43, and therefore a loss in critical RNA processing, has a 
profound effect on neuronal homeostasis, leading to disease. 
 
1.4 Post-Translational Modifications of TDP-43 
 A critical step in TDP-43-related pathology is thought to be aberrant 
phosphorylation of multiple residues in the C-terminal domain including Ser379, 
Ser403, Ser404, Ser409 and Ser410 (79).  The exact sites of phosphorylation were 
initially investigated through antibodies specific for phospho-epitopes of TDP-43.  
The 5 sites were confirmed to be phosphorylated in inclusions found in the brains 
of patients who were diagnosed with either ALS or FTD (79).  Next, in vitro kinase 
assays were used to determine that casein kinase 1 (CK1) was likely responsible 
for phosphorylating TDP-43 and that aberrantly phosphorylated TDP-43 formed 
SDS-insoluble oligomers (79).  Mass spectrometry confirmed the above 5 
phosphorylated residues in recombinant TDP-43 treated with CK1, in addition to 
24 other phosphorylated residues (80).  This work involved in vitro incubation of 
CK1 with recombinant TDP-43 and therefore non-biologically relevant 
phosphorylation could have occurred.  The kinase CDC7 may also be involved in 
phosphorylating TDP-43 (81). 
Additional studies compared patient-derived inclusions with fresh rat brain 
and found phosphorylated Ser409 (pSer409) and phosphorylated Ser410 
(pSer410) in the patient samples only (82).  In C. elegans models of ALS (TDP-43 
bearing a G290A, A315T, or M337V mutation) pSer409/pSer410 was detected, as 
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well as in the insoluble protein fraction of strains expressing wild-type TDP-43  
(25).  A phosphomimetic TDP-43 with Ser409Glu/Ser410Glu expressed in 
Neuro2A cells induced toxicity and cell death (83). These studies suggested that 
phosphorylation of these residues was not a normal post-translational modification 
of TDP-43.   
There is currently no evidence of the level of in vivo phosphorylation in a 
healthy cellular environment.  Without understanding this, it is difficult to 
understand exactly what sites are pathological during formation of TDP-43 
aggregates or when this aggregation occurs.  One theory is that as a result of 
disease pathogenesis, kinases become highly active and abnormal 
phosphorylation occurs thus leading to aggregation.  In a neuroblastoma cell line, 
aggregates containing phosphorylated C-terminal fragments of TDP-43 (residues 
220-414) were more slowly cleared by the ubiquitin-proteasome system (UPS) 
than unmodified fragments (84).   
 In an alternative theory, phosphorylation was proposed to occur after 
aggregation as a possible mechanism to facilitate clearance of the aggregates.  In 
HEK293T and Neuro2A cells, C-terminal fragments (residues 252-414) formed 
cytoplasmic aggregates that were phosphorylated at the expected five Ser 
residues: 379, 403, 404, 409 and 410 (85, 86).  The fragments were then mutated 
to contain either Asp/Glu (phosphomimetic) or Ala at the 5 phosphorylation sites.  
Fewer aggregates of the phosphomimetic C-terminal fragments were observed 
than the Ala fragments (86).  The reduction in aggregate formation suggested 
phosphorylation occurs as a means of protection from larger aggregate formation 
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(85, 86).  In a time course assay, more phosphorylated aggregates were detected 
at later than earlier time points (87, 88).  However, phosphomimetics in full length 
TDP-43 did not show a significant reduction in aggregation (86).   
Finally, disruption of the UPS with an inhibitor also led to increased 
phosphorylation and aggregate formation of mutant TDP-43 compared to cells with 
a functional UPS (89), suggesting that impaired protein degradation may also 
contribute to TDP-43 aggregation (88, 89). 
Though there is significant conflicting information, it appears that 
phosphorylation of TDP-43, at least at Ser409/Ser410, is not a normal event for 
TDP-43 function.  Elucidating the biochemical effect of phosphorylation would be 
an important piece of information in understanding the transition of soluble TDP-
43 to aggregate. 
 
1.5 Initial Evidence of Interactions 
When work with TDP-43 began in the Dunn lab, it was observed that a GST-
tagged, full-length TDP-43 protein (GST-NRG), expressed in Escherichia coli, was 
insoluble and spun down in the pellets of both low and high speed centrifugations 
(Figure 7A).  Much of the TDP-43 literature has described the intrinsically 
disordered C-terminal domain as aggregation prone, suggesting this may be 
contributing to the insolubility of the full length TDP-43. Two models of aggregation 
were then considered for explaining the insolubility of full length TDP-43 as 
demonstrated in Figure 7B.  The first suggests the C-terminal domain of one TDP-
43 molecule interacting with the N-terminal or RNA-binding domain of another 
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TDP-43.  The free C-terminal domain then binds with another TDP-43, causing a 
continually oligomerizing chain.  The second depends only on the intrinsic 
aggregation of the C-terminal domain: many C-terminal domains interact, creating 
many punctate aggregates.  Of the two models, the first would be more easily 
remedied by creating a split construct that would express the C-terminal domain 
as a separate polypeptide from the rest of the tagged TDP-43 molecule.  This was 
achieved by inserting a ribosome re-initiation site (RRS) consisting of overlapping 
translational termination and initiation codons between the RNA-binding domain 
and C-terminal domain (Figure 7C).  When this mRNA is expressed the ribosome 
would translate the GST-NR polypeptide and terminate at the stop codon, but 
remain bound to the mRNA due to the presence of a weak Shine-Delgarno site.  
Translation would then begin again, synthesizing the G polypeptide in a theoretical 
1:1 ratio to GST-NR (Figure 7D).  After induction of this plasmid and the same 
extraction conditions, the split in TDP-43 was observed to reduce the level of 
insoluble protein and both polypeptides remained in the high speed supernatant 
(Figure 7E).  This dual expression allows for any interdomain interactions in TDP-
43 while preventing the large aggregate formation (Figure 7F).  
With soluble protein, the next step was to purify the two TDP-43 
polypeptides separately.  To achieve this, a number of column chromatography 
techniques were used, including ion exchange (DEAE-Sepharose; IX), to separate 
the polypeptides based on their differing intrinsic properties.  What was observed 
was coelution of GST-NR and G, even after consecutive IX columns.   
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Figure 7. Justification for construction of the split TDP-43 construct, GST-NR_G.  
A) Coomassie stained gel showing the aggregated GST-TDP-43, located in the 
pellets of cell lysates (red arrow).  B) Two proposed models of aggregation of TDP-
43 (yellow: N-terminal domain; green: RRM domains; blue: C-terminal domain).  
C) Schematic diagram of the split TDP-43 plasmid.  D) Schematic of the two 
polypeptides, GST-NR and G (bottom), created with the plasmid in C), compared 
to full length GST-TDP-43 (top).  E) Coomassie stained gel of the now soluble 
GST-NR (top red arrow) and G (bottom red arrow) polypeptides.  F) Model of how 
GST-NR and G can interact without forming any large aggregates. 
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Figure 8 shows the result of one such IX column, DEAE-Sepharose.  Lanes 6-10 
show GST-NR and G eluting in the same fractions through the applied NaCl 
gradient, though G was not expected to interact with the column.  The two 
polypeptides were confirmed by mass spectrometry using a concentrated fraction 
from this analysis (Figure 8, Lane 16).  This observation introduced an interesting 
theory that intra- or intermolecular interactions may form between the two 
polypeptides and the existence of such an interaction became the hypothesis of 
this thesis work. 
 
1.6 Intrinsically Disordered Protein Regions 
Intrinsically disordered protein regions (IDPRs) do not form rigid secondary protein 
structures, but rather form transient structures dictated by nearby binding partners 
or environmental factors (22, 23).  IDPRs in some proteins have autoinhibitory 
functions through intramolecular interaction with a functional domain of the same 
polypeptide and inhibit functions such as subcellular localization, ligand interaction 
and enzymatic function (92, 93).  Relieving inhibition may involve post-translational 
modification (commonly phosphorylation), proteolysis or ligand binding (92, 93).  
Known autoinhibited proteins include CaMKI, Src and moesin (93).  For example, 
the C-terminal domain of moesin is an IDPR which binds intramolecularly to its 
FERM domain, inhibiting interactions with binding partners of moesin (93, 94).  
While bound, the C-terminal domain adopts a helical secondary structure.  After 
phosphorylation of a threonine residue within this domain, it is thought that the  
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Figure 8. Coelution of the GST-NR (58 kDa) and G (16 kDa) polypeptides, 
indicated by the two red arrows.  Lane 2 shows the sample loaded on the column.  
Lane 3 is the flow-through proteins.  Lanes 4-14 show the eluted proteins through 
the NaCl gradient.  Lane 16 shows the concentrated eluted protein run on a 
separate gel, the bands indicated by arrows were analyzed by mass spectrometry.  
The upper band was GST-NR and the lower band G. 
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helical structure is destabilized, causing a loss of binding and therefore inhibition 
(93, 94).  We postulate that a similar interaction may exist in TDP-43. 
  Some models for intramolecular interaction of TDP-43 domains are shown 
in Figure 9.  The C-terminal domain may interact with either the N-terminal or RNA-
binding domain of the same TDP-43 molecule, a region of another TDP-43 
molecule or involve a mediator protein.  There is no current evidence for 
autoinhibition by the C-terminal domain, but there are regions of the C-terminal 
domain that participate in protein interactions and aggregation.  As previously 
discussed, the C-terminal domain also contains at least 2 serine residues, S409 
and S410, that are confirmed to be phosphorylated in many patients with 
neurodegenerative disease (21).  These phosphorylation events could be 
evidence for autoinhibition because as previously mentioned, by means of 
relieving inhibition is post-translational modification.  However, the physiological 
levels of phosphorylated TDP-43 and its functional role have yet to be determined. 
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Figure 9. Different proposed models of intra- and intermolecular interactions by the 
TDP-43 C-terminal domain.  A) The non-interacting form of TDP-43.  The N-
terminal domain is indicated in yellow, the RNA-binding domain is indicated in 
green and the C-terminal domain in blue.  B) The C-terminal domain folds and 
makes many interactions with the N-terminal domain and RNA-binding domains.  
C) Only a small region of the C-terminal domain is involved in interactions with the 
RNA-binding domain.  D) Only a small portion of the C-terminal domain is involved 
in interactions with the N-terminal domain.  E) The interaction is intermolecular and 
involves two TDP-43 molecules.  F) A potential mediator protein (indicated by red) 
serves as an intermediary between the domains of TDP-43. 
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1.7 Hypothesis 
Developing a more thorough understanding of TDP-43 and its normal, 
biological structure and function is necessary for finding the critical events leading 
to disease onset.  My hypothesis is that the C-terminal domain of TDP-43 is 
involved in intra- or intermolecular interactions (Figure 10).  To test this hypothesis 
I will create constructs expressing specific regions of TDP-43 and subject them to 
various biophysical and cell biology techniques to elucidate possible interdomain 
interactions.  The constructs will be studied in isolated conditions to reconstitute 
interactions and to confirm the important binding region within the C-terminal 
domain. 
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Figure 10. Cartoon diagram of the predicted binding of TDP-43 domains.  When 
TDP-43 is in a monomeric “closed” state, the C-terminal domain (blue) forms an 
intramolecular interaction with the N-terminal domain (yellow) or RNA-binding 
domain (green).  The dimeric “closed” state is included because its formation is 
also possible since TDP-43 has been observed as a dimer.  In the “open” state, 
the intramolecular interaction has been relieved. 
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Chapter 2: Experimental Procedures 
2.1 TDP-43 Construct Cloning 
 The TDP-43 coding construct used in this study was provided by Dr. 
Kathryn Volkening.  This was a neuronal variant of TDP-43, cloned from human 
brain which encodes a 416 amino acid TDP-43 variant.  Its isolation and 
expression was reported by Strong et al (2007) (18). 
 The proteins used in this study were all cloned into the parent plasmid, 
pEBT7, which contains a T7 promoter, ampicillin resistance gene and an N-
terminal TEV cleavable His6-Thioredoxin- (HT-) tag (95).  Any plasmids were 
isolated by alkaline lysis or QIAprep Miniprep extraction from MM294 or BL21DE3 
E. coli cells.  After restriction endonuclease (RE) digestion, all DNA fragments were 
run on 0.8% agarose gels and purified by excision from the gel and repeated 
freezing at -20°C and thawing.  The final thawed sample was centrifuged in a 
desktop centrifuge through fibre floss to extract the DNA.  The plasmids pCB1, 
pSD600, pSD639, pSD747, pSD748 and pSD749 were made by Yumin Bi and Dr. 
Stan Dunn and were used throughout this work. 
The plasmid pKD006 was made by ligating the 1257-bp BamHI/HindIII 
fragment from pCB1 with the 1320-bp HindIII/PstI and 4495-bp PstI/BamHI. 
fragments from pEBT7. pKD006 expressed full- length TDP-43 with an N-terminal 
HT tag.  The plasmid pKD004 was made by ligating the 790-bp BamHI/HindIII 
fragment from pSD600 with the 1320-bp HindIII/PstI and 4495-bp PstI/BamHI 
fragments from pEBT7.  pKD004 expressed the N-terminal and RNA-binding 
domains with an N-terminal HT tag. 
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 Quickchange mutagenesis by PCR was used to create a number of 
mutations to pSD639, which expressed the C-terminal domain with an N-terminal 
HT tag.  The reactions with the forward and reverse primers were carried out in 
separate tubes and utilized the KOD Hot Start DNA polymerase (EMD Millipore 
Corp).  The thermocycler protocol started at 94°C for 5 min, then cycled [94°C for 
40 s, 55°C for 40 s, 72°C for 5 min] 30 times.  The forward and reverse reactions 
were combined and returned to the thermocycler for annealing—95°C for 5 min, 
90°C for 1 min, 80°C for 1 min, 70°C for 30 s, 60°C for 30 s, 50°C for 30 s, 40°C 
for 30 s and 37°C hold.  The DNA was then cleaned up with a PCR cleanup kit 
(BioBasic Canada Inc., Markham ON) and DpnI-digested to degrade the template 
DNA.  Table 1 outlines the plasmids made by this method. 
Further cloning by Quickchange mutagenesis was performed to construct a 
set of plasmids that express truncated versions of the C-terminal domain variants.  
Forward and reverse primers were designed to insert a second BamHI site within 
the C-terminal domain gene sequence.  PCR reactions were run and digested as 
previously described.  Purified plasmids were then digested with BamHI and the 
5917-bp or 5878-bp fragment was ligated by itself, creating the truncated C-
terminal fragment.  Table 2 outlines the plasmids made by this method. 
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Plasmid Name Primers (5’ to 3’) 
pKD011 HT-G-M337V 
F:CAGTTGGGGTATGGTGGGCATGTTAGC 
R:GCTAACATGCCCACCATACCCCAACTG 
pKD012 HT-G-Δ407 
F:CTCAAGCATGGATTAAGTCTTCTGGCTG 
R:CAGCCAGAAGACTTAATCCATGCTTGAG 
pKD013 HT-G-S409D 
F:CTCAAGCATGGATTCTAAGGAATCTGGCTGGGG
AATGAATC 
R:GATTCATTCCCCAGCCAGATTCCTTAGAATCCAT
GCTTGAG 
pKD015 HT-G-S410D 
F:GCATGGATTCTAAGTCTGAAGGCTGGGGAATGA
ATCAC 
R:GTGATTCATTCCCCAGCCTTCAGACTTAGAATCC
ATGC 
pKD017 HT-G-SS409DD 
F:GTTAGTGATTCATTCCCCAGCCkTCkTCCTTAGAA
TCCATGCTTGAGCCAAAGCCTCCATTAAAAC 
R:GTTTTAATGGAGGCTTTGGCTCAAGCATGGATTC
TAAGGAkGAkGGCTGGGGAATGAATCACTAAC 
pKD027 HT-G-ΔNH 
F:GGCTGGGGAATGTAACCTAGGAAGC 
R:GCTTCCTAGGTTACATTCCCCAGCC 
pKD028α HT-G-S409D-ΔNH 
F:GGCTGGGGAATGTAACCTAGGAAGC 
R:GCTTCCTAGGTTACATTCCCCAGCC 
F-forward primer; R-reverse primer; k-G or C in sequence; α-parent plasmid was pKD013 
 
Table 1. List of plasmids and primers constructed by Quickchange mutagenesis. 
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Plasmid Name 
Parent 
Plasmid 
Primers (5’ to 3’) 
pKD019 HT-G386-416 pSD639 
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG 
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG 
pKD020 HT-G399-416 pSD639 
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG 
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG 
pKD021 HT-G386-406 pKD012 
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG 
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG 
pKD022 HT-G399-406 pKD012 
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG 
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG 
pKD023 HT-G386-416S409D pKD013 
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG 
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG 
pKD024 HT-G399-416S409D pKD013 
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG 
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG 
pKD025 HT-G386-416DD pKD017 
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG 
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG 
pKD026 HT-G399-416DD pKD017 
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG 
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG 
F-forward primer; R-reverse primer 
 
Table 2. List of plasmids and primers constructed by Quickchange mutagenesis, 
based on the parent plasmid, pSD639. 
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2.2 Protein Expression and Cell Lysis 
 The relevant expression plasmids for the various TDP-43 constructs were 
transformed into and expressed from the E. coli strains, MM294 and BL21DE3.  
For a large cell growth, one transformed E. coli colony was added to 25 mL of liquid 
LBamp and incubated for 3 h (37°C, shaking) until a density of 0.1 absorbance at 
600 nm (A600) was reached. Ten µL of a 10x dilution of this growth was added to 1 
litre 2xYTamp media (Yeast Extract Tryptone media) and grown overnight at 30°C, 
shaking, to an A600 of 0.6.  Protein expression was induced by adding 120 mg of 
IPTG and growth continued for 6 h (37°C, shaking).  Cells were collected by low 
speed centrifugation in a Beckman JA-9.1 rotor (6k rpm, 10 min) and resuspended 
in 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, buffer to a 50% suspension 
and stored at -80°C for later use. 
The induced cells were lysed using a French Pressure Cell.  Two mL of the 
50% induced cell suspension were added to 30 mL of lysing buffer, containing 50 
mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, plus 1 mM PMSF.  The cell lysate 
was centrifuged at low speed in a Beckman JA-25.5 rotor (10k rpm, 10 min, 4°C), 
the supernatant was collected and centrifuged again at high speed (38k rpm, 90 
min, 4°C) in a Beckman 70.1Ti rotor.  If the TDP-43 polypeptide was soluble, the 
final supernatant was stored at -80°C for future experimentation.  Some of the 
variants expressed as inclusion bodies and were initially stored as pellets.  
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2.3 Protein Expression by Mini-Induction 
For some of the experiments, induced cell extracts were required in small 
amounts.  A transformed colony was added to 5 mL of LBamp and grown in a 37°C 
water bath, shaking.  At an A600 of 0.1, the cultures were induced with 0.55 mM 
IPTG and allowed to grow to stationary phase.  The induced cells were centrifuged 
and resuspended in 1x SDS-PAGE sample buffer with 50 mM DTT and boiled for 
5 minutes.  These extracts were frozen at -20°C for later use. 
 
2.4 TDP-43 Construct Purification 
 TDP-43 is a highly aggregation-prone protein and the purification of the 
overexpressed constructs for this work was complicated.  The following are the 
different procedures developed to prepare the TDP-43 variants that were purified 
for this work.  Proteins were analyzed by SDS-PAGE using 15% polyacrylamide 
gels and a Tris-Tricine running buffer (96).  SDS protein samples were prepared 
with denaturing sample buffer with 50 mM DTT (SB+).  The protein bands were 
visualized by staining the gel with Coomassie Blue G.  The protein concentration 
at various steps was determined by the Bio-Rad Protein Assay (reagent from Bio-
Rad Laboratories) by comparing sample absorbance at 595 nm to a calibration 
curve of known BSA concentrations. 
 
2.4.1 HT-NR purification—This protein was soluble after initial centrifugation.  The 
first step in purification was a 40% saturated ammonium sulfate (NH4SO4) 
precipitation, achieved by adding 100% saturated NH4SO4 directly to the retrieved 
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supernatant. At 40% saturation, the majority of the HT-NR polypeptide precipitated 
and after centrifugation at 4°C in a Beckman JA-25.5 rotor, the NH4SO4 
supernatant was removed and the pellet was dissolved in 50 mM Tris-HCl, 100 
mM NaCl, 10 mM imidazole, pH 8.0.  This buffer was selected because it is 
compatible with an immobilized metal affinity column.  Before loading the 
resolubilized protein on the column, it was centrifuged at 13,000 rpm for 20 min in 
a desktop centrifuge to remove any insoluble particles. 
 A column containing 10 mL of Chelating Sepharose was charged with Ni2+ 
(Ni2+ affinity column) to utilize the His6-tag on HT-NR.  At room temperature, the 
HT-NR solution was loaded onto the column and the flowthrough (FT) was 
collected.  Since the HT-NR polypeptide contains the RNA-binding domain, the 
column was washed with 10 column volumes of 200 mM NaNO3 and 1 M NaCl to 
dissociate any bound nucleotides.  To elute the bound protein, an elution buffer 
containing 50 mM Tris-HCl, 100 mM NaCl and 500 mM imidazole, pH 8.0, was 
added in 5-mL aliquots, with 5-mL fractions collected.  The fractions containing the 
highest levels of HT-NR were identified by SDS-PAGE, pooled and adjusted again 
to 40% saturated NH4SO4 to precipitate the protein as before.  After centrifugation, 
the resulting pellet was collected and redissolved in 2 mL of 750 mM arginine 
hydrochloride (ArgHCl), 50 mM Tris-HCl, 1 mM DTT, pH 8.0 to concentrate the 
HT-NR and prepare it for further purification.  ArgHCl was added to disrupt any 
unwanted protein interactions that were maintained through the first column and 
separate the contaminating species through a second purification column, gel 
filtration.   
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 A 200 mL column containing Sephacryl S-200 resin (S200) was equilibrated 
with the 750 mM ArgHCl, 50 mM Tris-HCl, 1 mM DTT, pH 8.0, buffer and the 
protein sample was loaded on the column and maintained at 4°C.  The same buffer 
was used to run the column, collecting 1-mL fractions at 2 mL/h.  As before, the 
fractions with the highest level of protein were identified by SDS-PAGE, pooled 
and precipitated with 40% saturated NH4SO4.  The precipitate was centrifuged as 
before and redissolved in 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, buffer 
and centrifuged again in preparation for the final purification column. 
 A 23 mL Q-Sepharose ion exchange (IX) column connected to an 
AKTAexplorer HPLC was equilibrated with 50 mM Tris-HCl, 1 mM EDTA, 1 mM 
DTT, pH 8.0, at room temperature.  The redissolved HT-NR protein was loaded 
onto the column and eluted with a 6-column volume 0-1 M NaCl gradient in 50 mM 
Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0.  The presence of eluted protein was 
monitored by reading absorbance at 280 nm (A280) of each fraction, further 
identified by SDS-PAGE, pooled and dialyzed against 50 mM Tris-HCl, 1 mM 
EDTA, 1 mM DTT, pH 8.0, for storage at -80°C as this final step resulted in pure 
HT-NR protein. 
 
2.4.2 HT-G purification—The HT-G polypeptide was purified by Dr. Stan Dunn and 
as undergraduate project work by Christina Chung, Thamiya Vasanthakumar and 
Jethro Kwong (97, 98).  Briefly, overexpression of HT-G in E. coli formed an 
inclusion body that sedimented in the low speed pellet after lysis.  The inclusion 
body was washed and resolubilized in 4 M guanidine hydrochloride (GuHCl), 10 
43 
 
 
mM Tris-HCl, 0.1 mM EDTA, 10 mM imidazole, pH 8.0 then loaded onto a Ni2+ 
affinity column.  To facilitate refolding of the denatured HT-G, the column was 
washed with 100 mM Tris-HCl, 30% dimethylformamide, 10 mM imidazole, pH 8.0, 
then with 100 mM Tris-HCl, 10 mM imidazole, pH 8.0.  The column was washed 
again with 750 mM ArgHCl, 100 mM Tris-HCl, 10 mM imidazole, pH 8.0, and finally 
750 mM ArgHCl, 100 mM Tris-HCl, 250 mM imidazole, pH 8.0, to elute the bound 
protein.  The eluted protein was pooled and stored at -80°C. 
 HT-G was dialyzed at room temperature against 1 mM trifluoroacetic acid 
(TFA) in ddH2O, then 0.1 mM TFA.  Since TFA is acidic, a further dialysis was 
done with 25 mM Tris-HCl, 0.1 mM TFA and 1 mM TCEP, pH 7.5 or 25 mM Tris-
HCl, 25 mM Tricine and 1 mM TCEP, pH 7.3, to neutralize the solution for further 
work.  Dialysis against 25 mM Tris base, 50 mM Tricine, 1 mM TCEP, pH 7.5 also 
maintained HT-G solubility and was used in some work. 
 
2.4.3 C-terminal domain mutant purification—Two of the deletion mutant 
polypeptides, HT-G386-416 and HT-G386-406, were purified.  Much of the aggregation 
prone region of the C-terminal domain was deleted and therefore after cell lysis, 
the two constructs were soluble after the high speed spin.  Both were purified by 
the same procedure as follows. 
 After centrifugation, the supernatants were 40% saturated NH4SO4 
precipitated, centrifuged at 13,000 rpm at 4°C and the pellet was resuspended in 
50 mM Tris-HCl, 100 mM NaCl and 10 mM imidazole, pH 8.0, for loading on a Ni2+ 
affinity column.  The bound protein was washed with 5 column volumes of 50 mM 
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Tris-HCl, 100 mM NaCl, 10 mM imidazole, pH 8.0, then eluted as previously 
described in the HT-NR purification procedure.  Following elution from the Ni2+ 
affinity column, the fractions that contained the most protein were pooled and 
dialyzed against 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0.  Next, the 
samples were loaded onto the IX Q-column, as previously described.  Following 
elution, the fractions containing the polypeptides of interest were pooled, 70% 
saturated NH4SO4 precipitated and the pellets were redissolved in 25 mM Tris 
base, 50 mM tricine, 0.5 mM TCEP, pH 7.5.  The two HT-G variants were purified 
at this point and were stored for future analysis. 
 
2.4.4 HT tag purification—A volume of cleaved and Ni2+ affinity column purified HT 
tag was attained from Jethro Kwong, a member of the Dunn Lab.  This was 
dialyzed against 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, and loaded 
onto the IX Q-column, as described in section 2.4.1.  Following elution, the 
fractions containing HT were pooled, 70% saturated NH4SO4 precipitated and the 
pellet was redissolved in 25 mM Tris base, 50 mM tricine, 0.5 mM TCEP, pH 7.5, 
then stored for later use. 
 
2.5 Western Blot 
 Through many stages of this work, Western blots were used to verify the 
presence of TDP-43 polypeptides.  The standard methods for Western blotting 
were conducted as previously described (99). 
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The samples were run by SDS-PAGE long enough for the dye front to run 
off the 15% polyacrylamide gel.  The proteins were then electrophoretically 
transferred to an Immobilon polyvinylidene fluoride (PVDF) membrane at 0.25 A 
for 1 h in a carbonate blot buffer (99).  The blotted membrane was transferred to a 
blocking buffer containing 3% BSA in blot rinse buffer (10 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, 0.1% Tween 20 and 0.04% sodium azide, pH 7.4) and 
incubated for at least 2 h at room temperature while shaking.  The membrane was 
then rinsed 3 times in plain blot rinse buffer for 10 min.  Next, the buffer was 
exchanged for blot rinse buffer containing 0.3% BSA, the primary antibody was 
added at a dilution of 1:5,000 and the membrane was incubated for 2h at 23°C or 
overnight at 4°C.  Two polyclonal rabbit antibodies from Sigma-Aldrich were used 
to detect TDP-43.  The first was an anti-N-terminal antibody, with an immunogen 
of a synthetic peptide composed of residues 75-90 of TDP-43 (Product Number: 
SAB4200006).  The second was an anti-C-terminal antibody, with an immunogen 
of a synthetic polypeptide composed of residues 355-369 of TDP-43 (Product 
Number: T1580).  After a 2 h incubation at room temperature, the membrane was 
washed again with rinse buffer, exchanged with 0.3% BSA buffer and the 
secondary antibody (alkaline phosphatase conjugated goat anti-rabbit IgG, 
Jackson ImmunoResearch Laboratories) was added at a dilution of 1:5,000.  The 
membrane was incubated for 1h at 23°C then washed again with rinse buffer.  
Briefly, the alkaline phosphatase was reacted by incubating the membrane in 10 
mL of 100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 9.5, with 80 µL of BCIP 
solution (20 mg/mL in 100% dimethylformamide) and 60 µL NBT solution (50 
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mg/mL in 70% dimethylformamide).  The membrane was left to react until the 
desired level of detection of the alkaline phosphatase was reached, approximately 
10 minutes. 
 
2.6 Far Western Blot 
 In this method, the proteins to be blotted were expressed in 5-mL liquid 
cultures of BL21 E.coli.  After induction by IPTG, samples were created by 
centrifuging a volume of the liquid cell culture and resuspending the cells in 1xSB+ 
and placing in a boiling water bath for 3-5 min.  The cell extracts were analyzed by 
SDS-PAGE to begin the process of equalizing the loading of the desired proteins 
through subsequent dilutions and SDS-PAGE.  Once the desired loading amounts 
were detected, the samples were stored at -20°C for use in this analysis. 
 Probe proteins were labelled with 125I by Dr. Stan Dunn using the Iodogen 
procedure (100). 
 The blots were prepared as previously described using Immobilon 
membrane.  Following blocking and rinsing, the membranes were transferred into 
0.3% BSA blot rinse buffer and the radioactive probe was added at 50,000-100,000 
dpm/mL.  After an overnight incubation at room temperature, the blots were 
washed for 10 min to remove any unbound probe and air dried.  Finally, the blots 
were visualized with a Storm 820 phosphorimager (Amersham Biosciences). 
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2.7 Sedimentation Equilibrium and Velocity 
 The sedimentation experiments were conducted in a Beckman XLA 
Analytical Ultracentrifuge in an An60 Ti rotor. 
 For sedimentation equilibrium (SE), samples were loaded in a 6-channel 
centerpiece and maintained at 4°C.  The loaded protein concentrations had 
absorbances between 0.2-0.5 at A280 and were sedimented at 12,000-24,000 rpm, 
depending on the experiment.  The time allotted for sedimentation equilibration 
after acceleration also depended on the experiment but all scans had radial 
intervals of 0.003 mm and 10 replicates. 
 The SE data was fit to a single species model using GraphPad Prism 5.  
The distribution is described by the equation: 
𝐶 = 𝐶𝑜 ∙ exp [
ѡ2
2𝑅𝑇
∙ 𝑀𝑊𝑒𝑥𝑝(1 − ?̅?𝜌) ∙ (𝑥
2 − 𝑥𝑜
2)] + 𝐼𝑜                   Equation 1 
where C is the concentration at radius x, with a concentration Co at reference 
radius xo, ѡ is the angular velocity of the rotor, the calculated molecular weight of 
the protein is MWexp, ?̅? is the partial specific volume of the analyzed protein, ρ is 
the solvent density, R is the gas constant (8.314 x 107 erg ∙ mol−1 ∙ K−1), T is 
temperature in Kelvin and Io is the baseline correction. 
 For sedimentation velocity (SV), samples were loaded in a 2-channel 
centerpiece and maintained at 4°C.  The loaded protein concentrations had 
A280=0.2-0.5 and were sedimented at 45,000 rpm.  Scans were taken every 10 
minutes for a total of 30 scans, at a radial interval of 0.003 mm with 5 replicates.  
The sedimentation spectra were analyzed by the program Sedfit (downloaded from 
www.analyticalultracentrifugation.com) (101). 
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2.8 Transfections and Colocalization 
 To complement the in vitro studies, in vivo colocalization studies with the 
same TDP-43 domains were carried out by Cheryl Leystra-Lantz and Dr. Cristian 
Droppelmann in the Strong Lab.  Briefly, four plasmids expressing fluorescently 
labelled NR and G polypeptides were constructed: GFP-NR, mCherry-NR, GFP-G 
and mCherry-G.  The plasmids were isolated by miniprep (Invitrogen) for 
transfection into HEK293T cells. 
 To visualize in vivo binding of NR and G by confocal microscopy, 
cotransfections with GFP-NR/mCherry-G or mCherry-NR/GFP-G were performed.  
The cells were plated at 1.25x105 cells/dish in 35 mm confocal dishes (MatTek).  
One µg of each plasmid was incubated with Lipofectamine 2000 at a 1:3 ratio and 
transfection was carried out as per the manufacturer’s protocol.  The cells were 
allowed to grow for 48 h then fixed with 4% paraformaldehyde paraformaldehyde 
in PBS for 10 minutes, washed in PBS and then visualized using the Meta510 
Confocal Microscope (Robarts Confocal Imaging Facility) at 600x magnification. 
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Chapter 3: Results 
3.1 TDP-43 Variant Plasmid Cloning 
 To generate materials for studying interdomain interactions in TDP-43, a 
plasmid library was created for this work that expressed variants of TDP-43 
including individual domains, truncations or point mutations, as described in 
Chapter 2.  The expressed TDP-43 has 416 amino acids and was isolated from 
human brain (36).  All variants were N-terminally tagged with a His6-Thioredoxin 
(HT) tag and were induced in the E. coli strain BL21DE3.  Figure 11 schematically 
shows the library of expressed polypeptides.  Throughout this work, the proteins 
will be referred to as their descriptive “Name” and not the plasmid number.  The 
proteins HT-NRG, HT-NR, HT-RG, HT-N, HT-R and HT-G all express various 
combinations of the wild-type TDP-43 domains, as indicated by their names. 
 Many variants of the C-terminal domain were also created to see how 
mutations or phosphorylation affected possible interdomain interactions.  HT-G-
M337V expressed the C-terminal domain with the common familial ALS mutation, 
Met337Val. 
The HT-G-Δ407 construct is a truncated C-terminal domain, missing 
residues 407-416.  This construct was created to eliminate the extreme C-
terminus, including the key Ser409/410 residues that were phosphorylated in 
aggregates. 
The constructs HT-G-S409D, HT-G-S410D and HT-G-SS409DD express 
mutations to the C-terminal domain that introduce an Asp (D) residue at the 
50 
 
 
phosphorylatable Ser409/410.  These mutations introduce a phosphomimetic 
residue that mimic the effects of phosphorylation on interaction. 
The remaining constructs were made to introduce further alterations to the 
previously mentioned C-terminal domain proteins.  Two truncations were made 
that deleted much of the C-terminal domain, expressing only residues 386-416 or 
399-416.  Similar deletions were also made to some of the previously mentioned 
mutants.  Additionally, the last two residues, Asn415 and His416, were deleted 
from two of the C-terminal domain constructs. 
 To verify that the new TDP-43 constructs contained the expected domains 
of TDP-43 and would blot sufficiently, SDS cell extracts of most of the constructs 
were blotted and probed with antibodies for the N-terminus and C-terminus of TDP-
43.  The HT-G constructs pKD019-026 were not blotted because the immunogen 
site was within the deleted residues.  Figure 12 shows the developed blots.  All 
polypeptides were detectable by the appropriate antibody.  HT-R was not detected 
by either antibody as expected.  There was some background signal with the 
antibodies but this was likely due to sample loading, degradation products or non-
specific binding by either the primary or secondary antibody. 
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Figure 11.  Schematic diagram of the TDP-43 variants used in this work.  The 
calculated molecular weight for each expressed protein is below each diagram.  
The red marker shows the location of an ALS associated mutation.  The green 
marker shows the location of a phosphomimetic mutation.  Unless indicated by 
subscript position numbers, HT-G constructs contain the full C-terminal domain, 
modified with the further descriptors. 
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Figure 12.  TDP-43 constructs detected by Western blot.  SDS cell extracts were 
prepared, blotted and probed with antibodies for the N-terminus and C-terminus of 
TDP-43.  The blotted constructs are labelled above.  The expected bands are 
starred (*).  Any other present bands are likely due to non-specific binding by the 
antibodies used, oligomeric species of the constructs or degradation species of the 
constructs. 
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3.2 Polypeptide Purification 
Pure proteins were required for some of the experiments in this work and 
were purified as outlined in Chapter 2. 
The first, HT-NR, was purified through a series of precipitations and 
columns, as demonstrated in Figure 13.  After lysis and centrifugation, the majority 
of the expressed HT-NR was soluble (Figure 13A).  It was precipitated by 40% 
saturated NH4SO4 and redissolved in 50 mM Tris-HCl, 100 mM NaCl and 10 mM 
imidazole, pH 8.0, buffer for loading on the Ni2+ affinity column (Figure 13B).  At 
this point, there was a possibility that RNA or DNA might still be bound to the RNA-
binding domain.  Therefore, the bound HT-NR was washed with 1 M NaCl and 200 
mM NaNO3, a chaotropic agent, in 50 mM Tris-HCl, 100 mM NaCl and 10 mM 
imidazole, pH 8.0, to disrupt the nucleotide interactions.  RNase and DNase were 
digests were attempted, however there was some interaction with the column and 
elution of the nucleases overlapped with the eluted HT-NR (data not shown).  The 
bound protein was eluted with 50 mM Tris-HCl, 100 mM NaCl and 500 mM 
imidazole, pH 8.0, and the fractions with HT-NR were pooled and precipitated by 
40% saturated NH4SO4 for transition into 750 mM ArgHCl, 50 mM Tris-HCl, 1 mM 
DTT, pH 8.0 (Figure 13C).  ArgHCl was used to solubilize the more concentrated 
HT-NR without structure denaturation and to assist in breaking up any protein-
protein interactions that survived the previous column.  The HT-NR was purified 
further by running through a gel filtration column (S200), equilibrated with 750 mM 
ArgHCl, 50 mM Tris-HCl, 1 mM DTT, pH 8.0 (Figure 13D).  In consecutive 
fractions, two peaks of HT-NR were observed: the first, centred around fraction 59,  
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Figure 13. Purification of the HT-NR polypeptide.  The red arrow indicates the band 
of interest, HT-NR.  A) SDS samples of the cell lysate, centrifugation supernatants 
(SN) and pellets (P) and initial 40% saturated NH4SO4 precipitation.  The low 
speed and high speed pellets were resuspended in an equal volume to the 
supernatant before sampling.  B) Sample of HT-NR loaded onto the Ni2+ affinity 
column and samples from the FT, wash and eluted protein.  C) SDS samples of 
the 40% saturated NH4SO4 SN and redissolved P of the pooled HT-NR eluted from 
the Ni2+ affinity column.  D) SDS samples of the loaded HT-NR and eluted 
fractions from the S200 gel filtration column.  The pooled fractions are indicated by 
the bracket.  E) SDS samples of the eluted HT-NR from the IX column.  The pooled 
fractions are indicated by the bracket.  F) An example of the final purified HT-NR 
for use in further study. 
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coeluted with an unknown E. coli protein and the second, centred around fraction 
66, contained predominantly HT-NR.  This second peak was pooled, precipitated 
by 40% saturated NH4SO4, then redissolved and dialyzed in 50 mM Tris-HCl, 1 
mM EDTA, 1 mM DTT, pH 8.0, for final purification by IX (Figure 13E).  HT-NR 
eluted between 250-350 mM NaCl and the most concentrated samples were 
pooled and stored for later use.  Figure 13F shows the final purified HT-NR protein. 
As previously mentioned, the HT-G purification protocol was established by 
Dr. Stan Dunn, Christina Chung, Thamiya Vasanthakumar and Jethro Kwong.  
Many different salts and buffering conditions were unsuccessful at preventing 
precipitation of HT-G.  The established procedure that successfully achieved 
soluble and purified HT-G was in a buffer containing 750 mM ArgHCl.  This 
construct contains the aggregation prone C-terminal domain of TDP-43 and 
ArgHCl was used to solubilize HT-G (102).  The high concentration of ArgHCl was 
not an ideal buffer condition for interaction studies, so it was necessary to find 
another buffer condition.  TFA is a known additive for dissolving and solubilizing 
aggregation prone proteins, including β-amyloid (103).  HT-G remained soluble 
after room temperature dialysis into 1 mM TFA, then 0.1 mm TFA in ddH2O (Figure 
14A).  To increase the pH, the TFA solubilized HT-G was buffered with Tris-HCl, 
pH 8.0, at various concentrations to determine solubility (Figure 14B).  Adding 25 
mM Tris-HCl, pH 8.0, maintained maximum solubility of HT-G and 1 mM of 
neutralized TCEP was added (Figure 14C). For some experiments, a buffer with a 
higher ionic strength was suitable since many proteins require such conditions to 
adopt proper structures and interactions.  Tricine is similar to Tris in structure 
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Figure 14.  Solubility trials of HT-G.  A) SDS-samples demonstrating HT-G in 
solution before (Arg750) and after dialysis into 0.1 mM TFA and centrifugation at 
13,000 rpm for 15 min (TFA0.1).  B) SDS samples of the tests for HT-G solubility 
after dialysis into 25, 50, 75 and 100 mM Tris-HCl, pH 8.0 (Tris25-100).  Each solution 
was centrifuged at 13,000 rpm for 15 min after dialysis.  C) SDS samples 
demonstrating the solubility of HT-G after addition of 1 mM neutralized TCEP 
(Tris25TCEP1).  D) SDS samples demonstrating that HT-G in 0.1 mM TFA 
remained soluble after dialysis against 25 mM Tris-HCl, 25 mM tricine, 1 mM 
TCEP, pH 7.3, and centrifugation at 13,000 rpm for 15 min (Tris25Tric25TCEP1).  E) 
SDS samples showing that HT-G in 750 mM ArgHCl was soluble after dialysis 
against 25 mM Tris base, 50 mM tricine, 1 mM TCEP, pH 7.5, and centrifugation 
at 13,000 rpm for 15 min (Tris25Tric50TCEP1). 
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but it is an acid rather than a base and has a more spread out charge distribution.  
HT-G in 0.1 mM TFA was dialyzed overnight into 25 mM Tris-HCl, 25 mM tricine, 
1 mM TCEP, pH 7.3, and remained soluble (Figure 14D).  TFA was not included 
in this dialysis because it is believed to bind directly to the protein and is not easily 
removed.  In an additional sample preparation, ArgHCl solubilized HT-G was 
dialyzed overnight against 25 mM Tris base, 50 mM tricine, 1 mM TCEP, pH 7.5, 
without any intermediate TFA dialysis.  HT-G was soluble under this condition and 
used in further studies (Figure 14E). 
The two polypeptides HT-G386-416 and H-G386-406 were purified through a 
series of precipitations and columns, as demonstrated in Figure 15A-D and Figure 
15E-H, respectively.  Both were purified by the same method.  After lysis and 
centrifugation, the majority of the expressed polypeptides were soluble (Figure 15A 
and E).  The high speed supernatants were precipitated by 40% saturated NH4SO4 
and redissolved in 50 mM Tris-HCl, 100 mM NaCl and 10 mM imidazole, pH 8.0, 
buffer for loading on the Ni2+ affinity column (Figure 15B and F).  Samples of the 
FT, wash and eluted protein are shown in Figure 15B and F.  The fractions that 
contained the highest amount of eluted protein were dialyzed against 50 mM Tris-
HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, for final purification by IX (Figure 15C and 
G).  Both HT-G mutants eluted between 230-360 mM NaCl and the most 
concentrated samples were pooled and stored for later use.  Figure 15D and H 
show the final purified HT-G386-416 and HT-G386-406, respectively. 
Finally, a purification of HT was performed to have a negative control for 
any influence of the tag during interaction experiments.  The sample acquired from  
59 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Purification of HT-G386-416 and HT-G386-406.  A-D are for HT-G386-416 and 
E-H are for HT-G386-406.  The red arrow indicates the band of interest.  A and D) 
Cell lysate, centrifugation supernatants (SN) and pellets (P).  The low speed and 
high speed pellets were resuspended in an equal volume to the supernatant before 
sampling.  B and F) SDS samples of the NH4SO4 SN and pellet (Ni2+ affinity load) 
and samples from the FT, wash and eluted protein from the Ni2+ affinity column.  C 
and G) SDS samples of the eluted HT-G386-416 and HT-G386-406 from the IX column.  
The pooled fractions are indicated by the bracket.  D and H) An example of the 
final purified HT-G386-416 and HT-G386-406 for use in further study. 
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Jethro Kwong was dialyzed against 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 
8.0, and loaded onto the IX column (Figure 16A).  HT mutants eluted between 240-
300 mM NaCl and the most concentrated samples were pooled, 70% saturated 
NH4SO4 precipitated and dialyzed against 25 mM Tris base, 50 mM tricine, 0.5 mM 
TCEP, pH 7.5.  Figure 16B shows the final purified HT. 
 
3.3 Far Western Blot 
3.3.1 Interactions with TDP-43 domains—The Far Western blot technique has 
been widely used to visualize protein-protein interactions (104).  To visualize the 
interactions, SDS-extracts of E. coli with the induced TDP-43 variants were 
separated by SDS-PAGE, blotted and incubated with a radio-labelled probe that 
was a suspected interactor.  Purified HT-NR and HT-N were both labelled with 125I, 
referred to as 125I-HT-NR and 125I-HT-N.  HT-N was purified by Jethro Kwong.  A 
Rhodobacter capsulatus F1-ATPase delta subunit, also fused to HT (HT-δ), is 
included in this experiment as a negative control.  The background E. coli proteins 
in the extracts acted as further controls for off-target binding by the probe.  The 
first blots were to test the interaction capability of 125I-HT-NR with the panel of 
wildtype TDP-43 domain variants.  Figure 17B shows the exposed blot and the 
corresponding Coomassie stained gel.  125I-HT-NR was observed to interact 
strongly with HT-NRG, HT-RG, HT-R and HT-G.  A weaker interaction was 
observed with HT-NR and almost no interaction was observed with HT-N.  There 
was no interaction with HT-δ.  Following this result, the interactions of 125I-HT-NR 
and 125I-HT-N were compared (Figure 17C).  The interactions observed with the   
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Figure 16.  Purification of the HT polypeptide.  A) SDS samples of the eluted HT 
fractions from the IX column.  The pooled fractions are indicated by the bracket.  
B) Final sample of purified HT. 
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125I-HT-NR probe were similar to those in Figure 17B.  However, much weaker 125I-
HT-N interactions were observed, with only faint signals for HT-NRG, HT-RG, HT-
R and HT-G.  These results indicated an interaction by either the N-terminal or 
RNA-binding domain with the C-terminal domain of TDP-43.  The weaker results 
with 125I-HT-N suggested a stronger influence by the RNA-binding domain for 
binding with the C-terminal domain.   
 
3.3.2 Interactions with C-terminal domain mutants—The C-terminal domain 
mutants were blotted and incubated with the probes to see how mutations or 
phosphomimetics affected interaction.  Figure 18A shows the results for interaction 
with 125I-HT-NR.  Strong interactions were observed with HT-G (Figure 17) and 
with HT-G-M337V.  The truncation in HT-G-Δ407 greatly reduced the interaction.  
A reduction in interaction was also observed with the phosphomimetic variants.  
HT-G-S409D had a weaker interaction signal than HT-G-S410D but similar to that 
of the double phosphomimetic.  These results indicate that the extreme C-terminus 
of the C-terminal domain is critical for interaction.  Two sets of repetitive blots were 
performed to verify these results (Figure 18B and C). 
 
3.3.3 Interactions with C-terminal domain deletions—To further analyze the 
importance of the extreme C-terminal domain to binding, the constructed deletion 
mutants were analyzed by Far Western blotting (Figure 19).  The HT-G positive 
control showed the expected binding with 125I-HT-NR.  There was no observable 
binding with any of the deletion mutants included.  This was a surprising result   
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Figure 17.  Far Western blot results for the panel of wild-type domains of TDP-43.  
A) Schematic diagram of the labelling of the TDP-43 domains.  B) Shows the 
Coomassie blue stained gel and exposed blot.  Ten microliters of the same 
samples were used for both the stained and transferred gels.  The TDP-43 variants 
were blotted and incubated overnight with the probe, 125I-HT-NR.  The radioactive 
signal was observed using a phosphorimager.  C) The two sets of TDP-43 variants 
were blotted on the same PVDF membrane, then the membrane was cut in half 
for separate incubation with either 125I-HT-NR or 125I-HT-N.  HT-δ is a negative 
control.  The signals were detected using a phosphorimager. 
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Figure 18.  Far Western blot results for the C-terminal domain variants.  A) Shown 
are the Coomassie blue stained gel and exposed blot.  The TDP-43 variants were 
blotted and incubated overnight with the probe, 125I-HT-NR.  B) and C) show 
duplicated sets of the C-terminal domain variants for monitoring reproducibility of 
the binding level.  The radioactive signal was observed using a phosphorimager. 
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Figure 19. Far Western blot results for the C-terminal domain deletion variants.  
Shown are the Coomassie blue stained gel and exposed blot.  The TDP-43 
variants were blotted and incubated overnight with the probe, 125I-HT-NR.  HT-G 
was included for a positive control and HT-G-Δ407 and HT-δ were included for 
negative controls.  
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for the constructs HT-G386-416 and HT-G399-416 especially, as they were expected to 
maintain some capacity for interaction.  It is possible that the binding region 
includes additional residues within the C-terminal domain and those remaining in 
these constructs were not sufficient to maintain an interaction to be detected by 
this method.  
 As mentioned in the introductions, TDP-43 is typically reported as a 414 
amino acid protein but this work has used a 416 amino acid isoform.  It was of 
interest to create the C-terminal domain variant with the last two residues deleted 
(HT-G-ΔNH, comparable to the 414 amino acid TDP-43) and compare its binding 
with 125I-HT-NR to the larger isoform.  In Figure 20A, three dilution levels of the C-
terminal domain variants were blotted.  As previously observed, HT-G-S409D had 
reduced binding compared to HT-G.  HT-G-ΔNH appeared to have increased 
binding compared to HT-G that was reduced in the phosphomimetic, HT-G-S409D-
ΔNH.  Visually, HT-G-ΔNH appeared to have 2x stronger binding with the probe 
than HT-G.  This was verified through repeated sets of HT-G and HT-G-ΔNH in 
Figure 20B. 
 
3.4 Analytical Ultracentrifugation 
 Analytical ultracentrifugation (AUC) is a useful tool for analyzing the solution 
behaviour of proteins including shape and interactions.  Both sedimentation 
equilibrium (SE) and sedimentation velocity (SV) were used in this work to further 
characterize the TDP-43 variants and their interactions. 
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Figure 20.  Far Western blot results for the C-terminal domain variant, HT-G-ΔNH.  
Shown are the Coomassie blue stained gel and exposed blot.  The TDP-43 
variants were blotted and incubated overnight with the probe, 125I-HT-NR. HT-δ 
was included as a negative control.  A) The four blotted variants were loaded at 
three dilution levels: 1 to 1, 1 to 2 and 1 to 4.  B) The 1 to 1 and 1 to 2 samples of 
HT-G and HT-G-ΔNH were blotted in triplicate to verify the reproducibility of the 
detected interaction level. 
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3.4.1 Sedimentation velocity of His6-Thioredoxin—To verify that the HT tag would 
not form homodimers, SV experiments were done to observe any concentration 
dependant dimer formation (Figure 21).  At increasing concentrations of purified 
HT (1.7 mg/mL, 2.8 mg/mL and 5.6 mg/mL), there was no change in the Sobs for 
the major sedimenting species.  Therefore, there was no dimerization of HT and it 
is a reasonable tag for further studies. 
 
 3.4.2 Classification of individual TDP-43 variants—Purified HT-NR and HT-G were 
first analyzed separately by SE and SV to establish the behaviour of each. 
 Purified HT-NR was dialyzed into 50 mM Tris-HCl, 0.1 mM EDTA, 1 mM 
TCEP, pH 8.0 and diluted to A280=0.25.  The protein was loaded into the centrifuge, 
as described in Experimental Procedures, for both SE and SV.  HT-NR sedimented 
as a single, monomeric species in both SE and SV experiments.  From SE, the 
experimental molecular weight (MWexp) was calculated to be 45.6 kDa by fitting 
the data to a global single ideal species model (Figure 22A).  HT-NR also 
sedimented largely as a single species with an observed sedimentation coefficient 
(Sobs) =2.08 S and with a fitted MWexp=42.6 kDa (Figure 22B).  The smaller peak, 
corresponding to a faster sedimenting species, was likely a small amount of HT-
NR homodimer.  This is consistent with the Far Western blots that had a low level 
of 125I-HT-NR interaction with HT-NR (Figure 17). 
 Purified HT-G was dialyzed into 25 mM Tris-HCl, 0.1 mM TFA, 1 mM TCEP 
and diluted to A280=0.25.  The protein was loaded into the centrifuge, as described 
in Experimental Procedures for both SE and SV.  HT-G sedimented as a single, 
70 
 
 
 
 
 
 
 
Figure 21. Sedimentation velocity experiments for various concentrations of HT.  
The cells were loaded with 1.7 mg/mL, 2.8 mg/mL or 5.6 mg/mL of purified HT in 
into 50 mM Tris-HCl, 0.1 mM EDTA, 1 mM TCEP, pH 8.0.  HT ?̅?=0.7383 mL/g, 
ρ=0.9984 g/mL and η=1.009 cP.  All samples were centrifuged at 45,000 rpm, 4°C 
and sedimentation was monitored by A280 every 10 min for 30 scans.  The data 
were analyzed by Sedfit, using a continuous c(s) distribution model. 
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Figure 22.  Equilibrium and velocity sedimentation results for HT-NR.  A) For SE, 
the cell was loaded with 0.22 mg/mL HT-NR in SV to establish the behaviour of 
each.  Purified HT-NR was dialyzed into 50 mM Tris-HCl, 0.1 mM EDTA, 1 mM 
TCEP, pH 8.0and sedimentation was observed by A280 after equilibration at 
12,000, 16,000 and 20,000 rpm at 4°C.  The data were fit to a global single ideal 
species model with a calculated MWexp= 45.6 kDa.  The calculated residuals are 
shown above the plot.  B) For SV, the cell was loaded with HT-NR at 0.23 mg/mL, 
centrifuged at 45,000 rpm at 4°C and sedimentation was monitored by A280 every 
10 min for 30 scans.  The data were analyzed by Sedfit, using a continuous c(s) 
distribution model.  A single species with Sobs=2.08 S and with a predicted 
MWexp=42.6 kDa.  Both SE and SV were analyzed with ?̅?=0.7349 mL/g, ρ=1.00145 
g/mL and η=1.017 cP.  C) Summary table of the information from the SE and SV 
experiments.  The polypeptide MW was calculated from the amino acid sequence 
and assumed removal of the N-terminal Met. 
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monomeric species in both SE and SV experiments.  From SE, the MWexp was 
calculated to be 22.2 kDa by fitting the data to a global single ideal species model 
(Figure 23A).  In SV, HT-G sedimented as a single species with a sedimentation 
coefficient=1.60 S and with a fitted MWexp=20.8 kDa (Figure 23B).  It is of note 
that the fitted molecular weights for both SE and SV were much lower than the 
calculated molecular weight. 
3.4.3 Sedimentation velocity of combined TDP-43 domains—SV experiments were 
then performed to see if the two isolated fragments of TDP-43 interact when mixed 
in solution.  In the first experiment (Figure 24A), HT-NR and HT-G were dialyzed 
into 25 mM Tris-HCl, 0.1 mM TFA, 1 mM TCEP, pH 7.3 and the individual 
polypeptides and the mixture were compared.  To detect transient or weak 
interactions, the slower sedimenting HT-G was added in excess to HT-NR to 
maximize the effect of weak binding by HT-NR as it sediments through HT-G.  The 
peaks corresponding to the HT-G boundary overlap and have similar Sobs (1.583 
S or 1.603 S).  In the combined experiment, the peak for HT-NR (2.267 S) was 
shifted to a larger Sobs compared to HT-NR only (2.174 S).  This suggested that 
there was residual binding with HT-NR and HT-G which increased the 
sedimentation rate of HT-NR.  HT-G was not similarly affected because it 
sedimented largely without HT-NR influence.  There is again a small peak in HT-
NR alone corresponding to a faster sedimenting species that is likely a small 
amount of HT-NR homodimer (S=3.472 S).  In the combined run, there is a similar 
faster sedimenting species that is shifted (S=3.560 S), likely due to interaction with 
HT-G.  The 25 mM Tris-HCl, 0.1 mM TFA, 1 mM TCEP, pH 7.5, buffer was very  
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Figure 23.  Equilibrium and velocity sedimentation results for HT-G.  A) For SE, 
the cell was loaded with 0.19 mg/mL HT-G in 25 mM Tris-HCl, 0.1 mM TFA, 1 mM 
TCEP and sedimentation was observed by A280 after equilibration at 14,000, 
16,000, 18,000 and 20,000 rpm at 4°C.  The data were fit to a global single ideal 
species model with a calculated MWexp=22.2 kDa.  The calculated residuals are 
shown above the plot.  B) For SV, the cell was loaded with HT-G at 0.19 mg/mL, 
centrifuged at 45,000 rpm at 4°C and sedimentation was monitored by A280 every 
10 min for 30 scans.  The data were analyzed by Sedfit, using a continuous c(s) 
distribution model.  A single species with Sobs=1.60 S was observed, with a 
predicted MWexp=20.8 kDa.  Both SE and SV were analyzed with ?̅?=0.7142 mL/g, 
ρ=0.9991 g/mL and η=1.009 cP.  C) Summary table of the information from the SE 
and SV experiments.  The polypeptide MW was calculated from the amino acid 
sequence and assumed removal of the N-terminal Met. 
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low in ionic strength which may not promote protein interactions.  Furthermore, 
while the concentration of TFA was low, it might also affect such interactions.  
Therefore, it was of interest to change to a different buffer. 
 The second experiment (Figure 24B) used 25 mM Tris-HCl, 25 mM tricine, 
1 mM TCEP, pH 7.3, as the sample buffer.  HT-NR was added in excess to HT-G.  
The sample of HT-G in this experiment was solubilized first in ArgHCl, then in TFA.  
TFA was left out of the final buffer for SV to reduce the effects of TFA on the 
structure and interactions made in solution.  The residual TFA after dialysis into 
the 25 mM Tris-HCl, 25 mM tricine, 1 mM TCEP, pH 7.3, should not have an effect 
on the results.  In the combined sample, there was a single sedimenting species 
detected with Sobs=1.789 S.  This boundary was sedimenting faster than HT-G 
alone (Sobs=1.711 S) and slower than HT-NR alone (Sobs=2.366 S).  There was 
also an even faster sedimenting species at Sobs=3.192 S in the combined sample. 
 In the third experiment, the polypeptides were dialyzed into 25 mM Tris 
base, 50 mM tricine, 1 mM TCEP, pH 7.5.  This sample of HT-G was dialyzed 
directly from ArgHCl and therefore was not exposed to any TFA to prevent any 
structural influence due to TFA binding.  HT-G was also added in excess to HT-
NR to provide the same opportunity for observing weak binding as in the initial 
experiment.  Figure 24C shows the results for this SV run.  Similar to the second 
experiment, when HT-NR and HT-G were mixed, a single sedimenting species 
was observed with a Sobs=1.697 S, which was again faster than HT-G alone 
(Sobs=1.555 S) and slower than HT-NR alone (Sobs=2.124 S).  A faster sedimenting 
species (Sobs=3.351 S) was again observed in the combined sample.  
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Figure 24.  Sedimentation velocity results of the HT-NR (solid), HT-G (dashed) and 
combined (dotted) in various buffers.  A) The cells were loaded with HT-NR (0.12 
mg/mL), HT-G (0.25 mg/mL) or Both (0.37 mg/mL), all in 25 mM Tris-HCl, 0.1 mM 
TFA, 1 mM TCEP, pH 7.3.  The Sobs are shown on the graph.  B) The cells were 
loaded with HT-NR (0.61 mg/mL), HT-G (0.29 mg/mL) or Both (0.90 mg/mL), all in 
used 25 mM Tris-HCl, 25 mM tricine, 1 mM TCEP, pH 7.3.  The Sobs are shown on 
the graph.  C) The cells were loaded with HT-NR (0.18 mg/mL), HT-G (0.18 
mg/mL) or Both (0.75 mg/mL), all in used 25 mM Tris base, 50 mM tricine, 1 mM 
TCEP, pH 7.5.  The Sobs are shown on the graph.  SV data were analyzed with HT-
NR ?̅?=0.7349 mL/g, HT-G ?̅? = 0.7142 mL/g, Both ?̅?=0.7246 mL/g, ρ = 1.0004 g/mL 
and η = 1.009 cP.  All samples were centrifuged at 45,000 rpm, 4°C and 
sedimentation was monitored by A280 every 10 min for 30 scans.  The data were 
analyzed by Sedfit, using a continuous c(s) distribution model. 
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 Again in these experiments, small peaks corresponding to a faster 
sedimenting HT-NR homodimer were observed in the HT-NR alone samples.   
 To test the theory that the extreme C-terminus of TDP-43 is responsible for 
binding, two of the deletion mutants were purified for analysis by SV.  HT-NR, HT-
G386-416 and HT-G386-406 were dialyzed against 25 mM Tris base, 50 mM tricine, 0.5 
mM TCEP, pH 7.5 and were loaded into the centrifuge.  The combination samples 
were loaded with a molar excess of the HT-G variants.  As a negative control, a 
sample of the HT tag was also purified and analyzed by SV.  In all experiments, 
the HT-G variant or HT was in excess to HT-NR. 
 Figure 25A shows the results for the SV with HT-G386-416.  It was predicted 
that this shorter region of the C-terminal domain would form a heterodimer with 
HT-NR that would sediment faster than HT-NR alone and would not form the 
extended structure as suggested in the previous experiment.  In the combined 
sample, the strongest boundary sedimenting at Sobs=1.392 S was faster than HT-
G386-416 alone (Sobs=1.065 S) and slower than HT-NR alone (Sobs=2.182 S).  A 
faster sedimenting peak at Sobs=2.695 S was also present in the combined sample.
 Figure 25B shows the results for the SV with HT-G386-406.  It was 
hypothesized that this even shorter region of the C-terminal domain would not 
participate in any interactions, as observed in the Far Western blot experiments.  
Again in the combined sample, a boundary was observed at Sobs=1.241 S that was 
sedimenting slightly faster than HT-G alone, Sobs=1.121 S, and slower than HT-
NR alone, Sobs=2.079 S.  There was again a faster sedimenting species at 
Sobs=2.412 S.    
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Figure 25. Sedimentation velocity results for the truncated HT-G constructs.  A) 
The cells were loaded with HT-NR (0.21 mg/mL), HT-G386-416 (0.18 mg/mL) or Both 
(0.39 mg/mL), all in 25 mM Tris base, 50 mM tricine, 0.5 mM TCEP, pH 7.5.  The 
Sobs are shown on the graph.  B) The cells were loaded with HT-NR (0.21 mg/mL), 
HT-G386-406 (0.18 mg/mL) or Both (0.39 mg/mL), all in 25 mM Tris base, 50 mM 
tricine, 0.5 mM TCEP, pH 7.5.  C) The cells were loaded with HT-NR (0.21 mg/mL), 
HT (0.17 mg/mL) or Both (0.38 mg/mL), all in 25 mM Tris base, 50 mM tricine, 0.5 
mM TCEP, pH 7.5.  The Sobs are shown on the graphs.  SV data were analyzed 
with HT-NR ?̅?=0.7349 mL/g, HT-G386-416 ?̅? = 0.7282 mL/g, HT-G386-406 ?̅? = 0.7304 
mL/g, HT ?̅?=0.7378 mL/g, BothA ?̅?=0.7316 mL/g, BothB ?̅?=0.7327 mL/g, BothC ?̅?= 
0.7364 mL/g, ρ = 1.0004 g/mL and η = 1.009 cP.  All samples were centrifuged at 
45,000 rpm, 4°C and sedimentation was monitored by A280 every 10 min for 30 
scans.  The data were analyzed by Sedfit, using a continuous c(s) distribution 
model. 
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 The final graph, Figure 25C, shows the results of the potential influence of 
pure HT on the sedimentation of HT-NR.  The two peaks in the combined sample 
were not well resolved in the analysis and the apparent shift in the slower 
sedimenting species, Sobs=1.195 S, may be influenced by the overlapping peaks.  
The peaks at Sobs=2.035 S and Sobs=2.093 S are likely both HT-NR monomers, 
the latter shifted due to the overlapping peaks or analysis variation.  
In all HT-NR experiments, a faster sedimenting species corresponding to 
an HT-NR homodimer was observed. 
 
3.5 In vivo Colocalization 
 HEK293T cells were cotransfected with fluorescently labelled NR and G, 
then visualized with confocal microscopy to observe colocalization by these 
polypeptides in vivo.  The cells expressed either GFP-NR/mCherry-G or mCherry-
NR/GFP-G; colocalization is indicated by yellow fluorescence due to overlapping 
GFP (green) and mCherry (red).  Figure 26 shows that in both combinations, there 
was colocalization of the two fragments of TDP-43 indicated by yellow 
fluorescence in the merged image.  It was also interesting to note that the NR 
fragment contains both the NLS and NES but both fragments appeared to localize 
to the nucleus.  This is demonstrated by the overlap of the blue Hoechst 
fluorescence with the red and green from the expressed polypeptides. 
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Figure 26. Confocal microscopy of fluorescently labelled TDP-43 domains in 
HEK293T cells.  The top row shows cells cotransfected with mCherry-G/GFP-NR 
and Hoechst stained.  The bottom row shows cells cotransfected with GFP-
G/mCherry-NR and Hoechst stained.  Both show colocalization of the two 
fragments of TDP-43.  The TDP-43 fragments also appeared to localize to the 
nucleus as indicated by the overlap with the blue fluorescence.  The images were 
taken at 600x magnification. 
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Chapter 4: Discussion, Conclusion and Future Direction 
4.1 Detecting TDP-43 Domain Interactions 
Two biophysical techniques, Far Western blotting and AUC, were used to 
investigate the existence of an interaction between the C-terminal domain and 
either the N-terminal domain or the RNA-binding domain of TDP-43.  Recombinant 
TDP-43 constructs containing various combinations of the three domains of TDP-
43 were used in these techniques and analyzed for intermolecular interactions.  
TDP-43 is a highly aggregation prone protein and it was difficult to isolate because 
it aggregated in inclusion bodies after overexpression in E. coli.  The recombinant 
polypeptides included a His6-thioredoxin (HT) tag that was utilized in affinity 
purification and in solubility.  E. coli thioredoxin is a well-studied molecule that 
increases solubility of proteins that are prone to form inclusion bodies, such as 
TDP-43 (104).  For this reason, the polypeptides were not cleaved from the HT-
tag for this work. 
 In a Far Western blot, the blotted polypeptides were probed with a 
radioactively labelled protein probe that was a suspected binding partner.  This 
technique requires a strong binding interaction that is detectable at very low probe 
concentrations compared to the blotted polypeptides during incubation and 
physical separation after significant washing to dissociate non-specific binding and 
excess radiation.  This is in contrast to AUC, where the two polypeptides were 
present in much higher concentrations and the faster sedimenting polypeptide is 
always in contact with its potential binding partner, maximizing the effects of an 
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interaction on the rate of sedimentation.  This situation is demonstrated in Figure 
27.  For this reason, much weaker interactions are detectable by AUC that may 
have presented as negative in a Far Western blot.  These two techniques 
complemented each other to establish both strength and minimal residue 
requirements of the domains of TDP-43 for interaction. 
4.1.1 The effects of buffers in AUC—The influence of various salts on protein 
stability in solution has been well studied and those that more closely mimic 
physiological levels are ideal for studying native interactions (105).  TDP-43 is an 
aggregation-prone protein and many of the typical buffers for AUC, particularly 
high salt buffers, were not suitable for studying interactions because they caused 
rapid precipitation of HT-G.  Some work was done to introduce low levels of NaCl 
into the buffer but HT-G rapidly precipitated and was not usable (data not shown).  
Instead, the purified domains were typically solubilized in buffers with components 
that prevent protein interactions/aggregation including ArgHCl (not used in AUC) 
and TFA, with low levels of Tris base and tricine.  TFA is a known additive for 
dissolving and solubilizing aggregation prone proteins, including β-amyloid (103).  
Adding TFA was useful for the initial AUC interactions studies with HT-G and there 
appeared to be some shift in the sedimentation of HT-NR.  However, the 
mechanism by which TFA solubilizes proteins is not well understood and it was not 
determined if TFA was removed with dialysis.  Therefore, it was of interest to find 
different conditions to further investigate binding to eliminate any possibility of TFA 
affecting interactions.  The solubility of HT-G in low levels of Tris-HCl, Tris base 
and tricine was critical to the interaction studies.  
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Figure 27. Schematic representation of the sedimentation of two species, with and 
without interaction.  The black figures represent the centrepiece where the sample 
is loaded for analysis.  White space is buffer.  Blue is the faster sedimenting 
species that over time, sediments to the back of the centrepiece.  Yellow is the 
slower species that sediments at a slower rate compared to blue.  Green 
represents the space where both species are sedimenting.  In a non-interacting 
system, the two species sediment at the same rates as observed individually.  In 
an interacting system, the blue species sediments at a faster rate than when alone 
because it is always in the presence of yellow (shown in green).  Yellow sediments 
at the same rate because it has lost contact with blue. 
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By dialyzing HT-G directly into a buffer with 25 mM Tris base and 50 mM tricine, 
the effects of bound TFA were eliminated and more reliable results achieved from 
the SV studies.   
 
4.1.2 The RNA-binding and C-terminal domains interact in Far Western blots—To 
investigate the ability of TDP-43 domains to interact, Far Western blots were used 
to visualize domain interactions by probing immobilized TDP-43 with purified 125I-
HT-NR or 125I-HT-N (Figure 17).  Strong interactions were observed between 125I-
HT-NR and HT-NRG, HT-RG, HT-R and HT-G while 125I-HT-NR/HT-NR had a 
weak signal.  No interaction was observed between 125I-HT-NR and HT-N.  These 
results suggested that the RNA-binding domain and C-terminal domain likely 
contained the major sites of interaction.  Therefore, it is possible that in the intact 
protein the intrinsically disordered C-terminal domain folds back to interact with 
RNA-binding domain to modulate some function of TDP-43 similar to that in other 
IDPRs (92, 93).  In TDP-43, this could involve RNA-binding or cellular localization 
by blocking the NES.  The C-terminal domain has been observed to bind other 
proteins (33, 42).  These interactions may relieve intramolecular inhibition by the 
C-terminal domain or may be blocked by the interaction.  In either case, cellular 
functions of TDP-43 would be modulated by a C-terminal/RNA-binding domain 
interaction. 
 The weaker interactions with 125I-HT-NR/HT-NR and 125I-HT-N with any of 
the blotted TDP-43 constructs suggest that TDP-43 may participate in additional 
interactions but these may only assist the stronger, RNA-binding/C-terminal 
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domain interaction or may require additional molecules such as RNA or proteins.  
Dimerization by the N-terminal domain has been observed through crosslinking 
techniques (48) and it is possible that Far Western blotting is not a sufficient 
technique for detecting this interaction. 
One common ALS mutation in the C-terminal domain, Met337Val, was also 
tested for interaction with 125I-HT-NR (Figure 18).  The level of interaction was 
similar to that of the wildtype HT-G.  It would be interesting in further work to 
compare this with other ALS mutations to see if there is a different result for the 
other known mutations.  It is not clear what the impact of the various mutations is 
on the fate of TDP-43 but comparing the interaction abilities of the mutants may 
provide some information. 
 
4.1.3 The extreme C-terminus is critical for interactions—In addition to binding with 
nucleotides or proteins, inhibition by IDPRs may also be relieved through post-
translational modifications such as phosphorylation (92, 93).  With some confirmed 
sites of phosphorylation within the C-terminal domain at Ser409/Ser410 (79), 
mutants of HT-G were created that contained phosphomimetic residues to observe 
the effects on the interactions detected by Far Western blotting (Figure 18).  In all 
three phosphomimetic constructs, binding with 125I-HT-NR was reduced.  Of the 
single phosphomimetics, HT-G-S409D showed a greater reduction in binding with 
125I-HT-NR than HT-G-S410D.  HT-G-S409D also had similar reduction to that of 
the double phosphomimetic.  A virtually complete reduction was observed in the 
deletion construct where residues 407-416 were deleted.  These results together 
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indicate that the extreme C-terminus of TDP-43 is important for the binding 
observed between the C-terminal domain and HT-NR.  Addition of a negative 
charge by the phosphate group to this region may interrupt the binding interface 
through steric hindrance or electrostatic repulsion. 
  
4.1.4 HT-NR and HT-G interaction increases sedimentation in solution—The 
interpretation of the data collected from the sedimentation velocity experiments 
was not entirely clear but some general trends were evident that do support the 
presence of an interaction.  Intramolecular interactions, such as the one 
hypothesized in this work, are likely weak in binding energy but are strengthened 
by proximity when both regions are within the same polypeptide (92).  By 
separating the interacting domains, the weaker interaction was more likely to be 
observed through a shift in the sedimentation boundary of monomers rather than 
a single heterodimer boundary.  In theory, the effect on sedimentation would be 
observable because the 45-kDa HT-NR polypeptide was both larger and less 
extended than the disordered, 30-kDa HT-G polypeptide and the HT-NR would 
therefore sediment more rapidly than HT-G.  If weak interactions occur, the 
heterodimer would sediment faster, shifting the apparent sedimentation of HT-NR 
to a larger Sobs.  HT-NR passing through a “sea” of HT-G would also increase that 
chances of multiple binding and release events, making the overall evidence of 
interaction more apparent.  The sedimentation of HT-G would not be as 
significantly influenced because that boundary would be separated from HT-NR 
during the experiment. (106) 
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 The shifts in the Sobs for the peaks in the first three SV experiments (Figure 
24) are summarized in Table 3.  In each experiment, the boundary assigned to HT-
NR sedimented more rapidly in the combined sample than the HT-NR alone.  The 
shift also increased as the buffer conditions became more favourable for protein 
interactions.  This result is as expected from the above explanation of 
sedimentation and interactions with HT-G and both the monomeric and 
heterodimeric forms of HT-NR were observed.   
 
4.1.5 The extreme C-terminus is not sufficient for interactions—The results 
discussed in the previous section supported an interaction by the C-terminal 
domain and implied that the extreme C-terminus was critical for the interaction.  All 
of the Far Western studies between HT-NR and wild-type HT-G showed a positive 
interaction.  When modifications were made to the extreme C-terminal region of 
HT-G through phosphomimetics or deletion, the interaction was reduced or nearly 
abolished.  The next step was to determine if this region was sufficient for the 
interaction. 
To further investigate the binding region of the C-terminal domain, mutants 
were constructed that deleted residues 262-385, leaving the extreme C-terminus 
attached to HT for interaction studies.  There was no observable interaction in the 
Far Western blots with either of the tested polypeptides (Figure 19).  This could be 
due to two situations: either how these proteins bound to the Immobilon membrane 
or else that more of the C-terminal domain contributes to binding.  In the first 
situation, accessibility of the probe to the blotted protein domain is dependent on   
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 Observed Sedimentation Coefficient (Sobs) Shift 
Buffer Condition 
HT-NR → Combined 
(Difference) 
HT-G → Combined 
(Difference) 
Tris25TFA0.1TCEP1 
Peak 1 
2.174 S → 2.267 S 
(0.0930 S) 
1.583 S → 1.603 S 
(0.020 S) 
Peak 2 
3.472 S → 3.560 S 
(0.088 S) 
Tris25Tris25TCEP1 
Peak 1 2.366 S → 3.192 S 
(0.826 S) 
1.711 S → 1.789 S 
(0.078 S) Peak 2 
3.754 S → 4.377 S 
(0.623 S) 
Tris25Tris50TCEP1 Peak 1 
2.124 S → 3.351 S 
(1.227 S) 
1.555 S → 1.697 S 
(0.142 S) 
 
Table 3.  Observed sedimentation coefficient shifts in SV experiments with HT-NR 
and HT-G.  Three different buffer conditions were used to study the same 
interaction.  Shown are the Sobs for the individual samples shifted (→) to the 
corresponding peak in the mixed sample.  The difference is provided in brackets.  
Peak 1 refers to the monomeric HT-NR boundary.  Peak 2 is the potentially 
homodimeric HT-NR boundary, if resolved by the analysis. 
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the orientation of the transferred protein on the Immobilon membrane and whether 
the binding site is accessible to the probe in solution.  In these small constructs, 
the binding region is so close to the His6-thioredoxin tag, there is a chance that the 
remaining residues of the C-terminal domain were inaccessible to the probe and 
therefore no binding could occur.  In the second case, there may be necessary 
residues for binding elsewhere in the C-terminal domain that were removed with 
both deletion mutants (HT-G-Δ407 and HT-G386-416) and deletion of either reduced 
the binding energy such that it was too low for the Far Western blot technique.  
Since the C-terminal domain is disordered, it is possible to have multiple sites of 
contact spread through the domain that individually have low binding energies but 
collectively create a strong interaction.  Through studying the binding kinetics of 
IDPRs, many of these domains adapt an induced fit structure that depends on an 
initial binding step that triggers a conformational change for full binding (reviewed 
in 107).  The final bound state would involve multiple sites through the domain and 
therefore weak binding may be detectable with many regions of the domain. 
 In the second set of SV experiments (Figure 25), a series of truncations 
were used to try to elucidate a more defined region of binding by the C-terminal 
domain.  Even though there was no detection of an interaction in the Far Western 
blot experiments with the HT-G386-416 construct, SV would present a more 
favourable environment for binding because the technique is more sensitive to 
weak binding due to the higher concentrations employed.  Table 4 summarizes the 
Sobs shifts for these experiments.  As anticipated, the shift in HT-NR sedimentation 
observed in the presence of HT-G386-416 was greater than that with HT-G386-406 or 
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HT.  This agrees with our prediction that there are residues within the extreme C-
terminus of TDP-43 that form an interaction with the RNA-binding domain.   
HT-G386-406 was expected to have no interaction with HT-NR based on the 
observation in the Far Western blot experiments with HT-G-Δ407.  However, the 
same sensitivity argument mentioned above for using SV applies here.  The 
residues in HT-G-Δ407 may not have had high enough binding energy to be 
detectable by a Far Western blot but the few remaining residues within HT-G386-406 
had a strong enough binding to increase the sedimentation of HT-NR detected by 
SV.  Overall, the extreme C-terminus of TDP-43 is critical to the interaction with 
HT-NR but it is not sufficient for high affinity binding.  The results suggested some 
binding energy is provided by other residues within the C-terminal domain. 
Finally, there was very little change in the sedimentation of HT-NR in the 
presence of the purified HT tag alone.  This confirmed that it is the presence of the 
C-terminal domain of TDP-43 that binds HT-NR and not the tag. 
 
4.1.6 Variation in Sobs due to Sedfit analysis and user error—As alluded to 
previously, the apparent shift in the HT boundary when in the presence of HT-NR 
may be attributed to the poor resolution of the two peaks during analysis.  There 
is also clear variation in the Sobs for identical polypeptides run in different 
experiments.  The software used for this analysis, Sedfit, required significant user 
input through placement of limits and boundaries during the analysis.  For 
example, if there is poor data collection due to a small leak during centrifugation, 
there may be fewer usable data points in one cell compared to another.  
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 Observed Sedimentation Coefficient (Sobs) Shift 
 
HT-NR → Combined 
(Difference) 
Other → Combined 
(Difference) 
HT-G386-416 
Peak 1 
2.182 S → 2.695 S 
(0.513 S) 1.065 S → 1.392 S 
(0.327 S) 
Peak 2 
3.718 S → 3.792 S 
(0.074 S) 
HT-G386-406 
Peak 1 
2.079 S → 2.412 S 
(0.333 S) 1.121 S → 1.241 S 
(0.120 S) 
Peak 2 
3.418 S → 3.631 S 
(0.213 S) 
HT 
Peak 1 
2.035 S → 2.093 S 
(0.058 S) 0.987 S → 1.195 S 
(0.208 S) 
Peak 2 
3.601 S → 3.704 S 
(0.103 S) 
 
Table 4. Observed sedimentation coefficient shifts in SV experiments with HT-NR 
and HT-G386-416, HT-G386-406 and HT.  Shown are the Sobs for the individual samples 
shifted (→) to the corresponding peak in the mixed sample.  The difference is 
provided in brackets.  Peak 1 refers to the monomeric HT-NR boundary.  Peak 2 
is the potentially homodimeric boundary. 
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This results in a smaller radial range of analyzable points, which has some impact 
on the observed sedimentation coefficients reported.  The radial range of data 
analyzed within an experiment (three SV data sets) was kept relatively constant 
but between experiments, the range was not as closely monitored.  This explains 
the variability in Sobs for HT-NR across the experiments but does not negate the 
larger shifts due to interaction.  Other sources of variability include cell alignment, 
window imperfections and temperature variability, to name a few.  In a study on 
the impact of such variables, Arthur et al. (2008) found that Sobs was not 
significantly affected by these variables (108).  Therefore, the above conclusions 
based on gross changes in sedimentation are more likely due to real interactions 
and not simply artifacts or experimental error. 
 
4.2 Implications for intramolecular interactions in TDP-43 function 
The functions of TDP-43 within a cell involve RNA-binding, protein-protein 
interactions and transport between the nucleus and cytoplasm (19).  These 
functions of TDP-43 must be tightly regulated by the cell to ensure that miRNA is 
correctly processed, or mRNA is spliced, transported or even degraded.  The 
presence of an IDPR within TDP-43, the C-terminal domain, suggests the 
possibility of this domain as a regulatory module that forms an intramolecular 
interaction to moderate TDP-43, for example, binding with RNA, binding with other 
proteins or even cellular localization. 
The most obvious role of the C-terminal domain would be in regulating or 
responding to RNA binding.  If the binding interface for the C-terminal domain 
96 
 
 
covers the RNA-binding surface, this intramolecular interaction could act by 
inhibiting RNA binding.  Relieving inhibition could involve post-translational 
modifications to the C-terminal domain or proximity to an intermolecular binding 
partner of TDP-43.  Alternatively, proximity to an ideal binding sequence within an 
RNA molecule could dissociate the C-terminal domain, making it available for 
protein interactions. 
Similar to that of RNA-binding, an intramolecular interaction by the C-
terminal domain could moderate access to the binding region for interactions with 
other protein binding partners of TDP-43 within a cell.  As discussed in Section 
1.2.4, the C-terminal domain participates in a number of protein-protein 
interactions and through an intramolecular interaction involving the C-terminal 
domain, these interactions could be inhibited.  Upon release, again by RNA-
binding or post-translational modification, the region for binding would be exposed 
to nearby proteins.  The C-terminal domain could then bind with the appropriate 
proteins for its current role, perhaps to be transported out of the nucleus.  Upon 
release of the protein partner after TDP-43 has completed its role, the C-terminal 
domain could rebind intramolecularly and once more shield interactions. 
TDP-43 contains both a NLS and a NES (31).  The C-terminal domain could 
act as a regulator of access to the NLS or NES.  The NES is located within the 
RNA-binding domain (residues 239-250).  The experiments in this work have 
suggested that the C-terminal domain forms an interaction with the RNA-binding 
domain.  In the bound state, the C-terminal domain may prevent recognition of the 
NES by transport machinery.  Masking of localization signals has been observed 
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in many other proteins (reviewed in 109).  Upon release of the C-terminal domain 
interaction by RNA-binding or post-translational modification, for example, the 
NES would be exposed and export of TDP-43 could occur.  TDP-43 would then be 
returned to the nucleus after rebinding of the C-terminal domain and subsequent 
masking of the NES.  TDP-43 aggregates are found localized to the cytoplasm of 
ALS-affected neurons and it is the C-terminal domain that is implicated in 
nucleating aggregation (1, 3, 31, 64, 110).  Loss of intramolecular binding by the 
C-terminal domain, possibly through excessive interactions leading to aggregation, 
may strand TDP-43 in the cytoplasm.  The in vivo confocal microscopy studies 
demonstrated that GFP-NR and mCherry-G expression were colocalized to the 
nucleus in HEK293T cells while little (if any) expression was seen in the cytosol.  
Considering the above discussion about the impact of the NES, there is also the 
consideration of the NLS, located within the N-terminal domain at residues 82-98.  
The structure formed by the N-terminal domain is just starting to be studied and it 
is possible that masking of the NLS also occurs within this domain.  At this time, 
the relative strength between the two signals is not known, but it would be 
interesting to study further. 
 
4.3 Implications for intramolecular interactions in TDP-43 
dependent pathogenesis 
 
4.3.1 ΔNH increased the interaction—The 416 amino acid isoform of TDP-43 used 
throughout this study was isolated from neuropathologically normal human brain 
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(18) but there is a 414 amino acid isoform that is more commonly cited in the 
literature.  The 414 amino acid isoform was originally isolated from HeLa cells (7) 
and is also detectable in HEK293T cells (18).  The longer isoform has two amino 
acid residues added at the C-terminus and its presence in the nervous system has 
interesting implications on the importance of the extreme C-terminus in TDP-43 
regulation.  While the expression of this isoform was not determined throughout 
human tissues, it would be interesting to determine if this isoform is neuronal tissue 
specific.  Deleting the last two residues of the 416 amino acid HT-G, making the 
HT-G-ΔNH C-terminal domain, appeared to increase binding with 125I-HT-NR 
about two-fold.  If intramolecular binding by TDP-43 is critical to stability and 
aggregation prevention, expression of the longer isoform in only certain tissues 
would explain the more aggregation-prone state of TDP-43.  The shorter isoform 
may form a more stable intramolecular interaction and therefore be less 
susceptible to the triggers for aggregation.  TDP-43 is a ubiquitously expressed 
protein, present in many different tissues (8), but its aggregation has thus far 
largely been observed in the nervous system.  There is some evidence for TDP-
43 involvement in inclusion body myopathy, a disease of the muscle, but the 
isoform of TDP-43 present in muscle was not determined (111).  Exploring this 
interaction further will be interesting for understanding the susceptibility of neurons 
to aggregation of TDP-43 and if it is related to the weaker binding isoform that is 
expressed. 
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4.3.2 Phosphorylation of C-terminal serines in TDP-43—As discussed in Chapter 
1, the aggregates found in neurons often contain TDP-43 phosphorylated at 
Ser409/Ser410 (82) and it is unclear whether phosphorylation or aggregation 
occurs first.  Considering the current results, arguments for both exist (Figure 28).  
If aberrant phosphorylation of the C-terminal domain occurred, a potentially critical 
step in moderating TDP-43 function would be disrupted, thus allowing for 
excessive interactions to occur and aggregate formation.  Alternatively, if 
aggregates of TDP-43 form, phosphorylation and cleavage may be preventative 
steps by a cell to reduce further aggregation with full length TDP-43 from occurring.  
In either case, disruption of this interaction could have an impact on the fate of 
TDP-43 in a neuron.  There has been little exploration into any in vivo pathways 
for dephosphorylation of TDP-43. 
 
4.4 Conclusion and Future Directions 
 My hypothesis was that the C-terminal domain of TDP-43 is involved in 
intra- or intermolecular interactions.  The experimental results presented in this 
work support my hypothesis and demonstrate that the C-terminal domain is 
capable of interaction with the RNA-binding domain of TDP-43.  Disruption of the 
interaction due to phosphomimetic mutations, similar to pathological 
phosphorylation, was also demonstrated.  I further hypothesize that this interaction 
could be critical to TDP-43 function within a cell and disruption is one critical step 
in disease pathogenesis.  Future work should be focused both in vitro and in vivo 
to further investigate the functional implications of an intramolecular interaction.  
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Figure 28.  Schematic diagram illustrating two possible functions of 
phosphorylation in aggregation.  On the left side, TDP-43 is aberrantly 
phosphorylated in the disease state which leads to aggregate formation.  On the 
right side, there is some trigger that causes TDP-43 to aggregate and 
phosphorylation of TDP-43 is a mechanism to prevent further aggregation.  
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 One important in vitro step should be purification of the full length TDP-43 
protein with greater yields.  This will provide an important piece of information for 
comparison with the current results.  More precise mapping of the binding interface 
within the RNA-binding domain would be important.  This could be achieved by 
introducing a crosslinking system where a photo-crosslinkable agent would be 
added in the C-terminal domain and upon binding and activation of crosslinking, 
the C-terminal domain would be chemically bound at the interface.  Then trypsin 
digestion and a peptide identification technique such as mass spectrometry could 
follow to identify the bound region in the RNA-binding domain.  Once a more 
precise region of interaction is known for both domains, site directed mutagenesis 
could be used to mutate certain residues that might be critical for an interaction 
and then perform the same interaction studies to determine the impact of the 
mutations. 
Investigation of the impact of oligonucleotides on the interaction would 
provide important information of what functions of TDP-43 might be regulated.  
Using a technique such as an electrophoretic mobility shift assay, a radio-labelled 
oligonucleotide could be added with the HT-NR and HT-G to observe how the 
movement of HT-NR and HT-G are altered by the presence of RNA.  The same 
techniques described in this work and future work should also be used to identify 
any differences in C-terminal domain binding due to other known mutations in 
disease.  This would complement purification of the mutant C-terminal domains 
and analysis by AUC.  Co-immunoprecipitation could also be used to detect an 
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interaction between co-expressed TDP-43 polypeptides from a eukaryotic cell 
lysate.   
 For in vivo work, more colocalization studies would be important for 
deciphering the biological relevance of the interaction.  This could be achieved 
through studies with lower construct expression and through introducing some of 
the other mutations or truncations used in this work.  Performing an RNA stability 
assay, such as a luciferase assay, would provide a more direct functional 
relevance of an interaction through observing the difference between full-length 
TDP-43 and the co-expression of NR and G polypeptides. 
 Overall, the work presented here is the initial step to defining an 
intramolecular interaction in TDP-43.  This is important to the field because it 
provides insight into the possible mechanisms of TDP-43 that may be altered in 
disease.  An interaction such as this has significant implications on how TDP-43 
should be studied both in the RNA-binding and neurodegenerative disease fields.  
The presence of the C-terminal domain in studies is variable depending on the 
desired results of the work, whether it be observing aggregation with an excess of 
this domain or determining structural behavior with the C-terminal domain cleaved.  
This type of interaction is critical to the normal behaviour of TDP-43 and therefore 
the C-terminal domain should not be cleaved for ease of purification or minimizing 
in vivo aggregation to properly study the natural behaviour of TDP-43.  Since TDP-
43 is a highly conserved protein, all domains are important to its function.  Through 
interdomain interactions, its variable roles within a cell could be much more tightly 
regulated and integral to cell survival than initially presumed.  Further efforts to 
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establish the molecular and biological basis for this interaction should provide 
better insight into the role of TDP-43 in normal cellular homeostasis and in disease 
pathogenesis.   
 
 
104 
 
 
 References 
1.  Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, 
D., Tsuchiya, K., Yoshida, M., Hashizume, Y., and Oda, T. (2006) TDP-43 is 
a component of ubiquitin-positive tau-negative inclusions in frontotemporal 
lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. 
Commun. 351, 602–611 
2.  Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., 
Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., McCluskey, L. 
F., Miller, B. L., Masliah, E., Mackenzie, I. R., Feldman, H., Feiden, W., 
Kretzschmar, H. A., Trojanowski, J. Q., and Lee, V. M.-Y. (2006) Ubiquitinated 
TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral 
Sclerosis. Science. 314, 130–133 
3.  Arai, T. (2014) Significance and limitation of the pathological classification of 
TDP-43 proteinopathy. Neuropathology. 10.1111/neup.12138 
4.  Van Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, 
L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., Steinbart, 
E., McCluskey, L., Grossman, M., Neumann, M., Wu, I.-L., Yang, W.-S., Kalb, 
R., Galasko, D. R., Montine, T. J., Trojanowski, J. Q., Lee, V. M.-Y., 
Schellenberg, G. D., and Yu, C.-E. (2008) TARDBP mutations in amyotrophic 
lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological 
analysis. Lancet Neurol. 7, 409–416 
5.  Yokoseki, A., Shiga, A., Tan, C.-F., Tagawa, A., Kaneko, H., Koyama, A., 
Eguchi, H., Tsujino, A., Ikeuchi, T., Kakita, A., Okamoto, K., Nishizawa, M., 
Takahashi, H., and Onodera, O. (2008) TDP-43 mutation in familial 
amyotrophic lateral sclerosis. Ann. Neurol. 63, 538–542 
6.  Al-Chalabi, A., Jones, A., Troakes, C., King, A., Al-Sarraj, S., and van den 
Berg, L. H. (2012) The genetics and neuropathology of amyotrophic lateral 
sclerosis. Acta Neuropathol. (Berl.). 124, 339–352 
7.  Ou, S. H., Wu, F., Harrich, D., García-Martínez, L. F., and Gaynor, R. B. 
(1995) Cloning and characterization of a novel cellular protein, TDP-43, that 
105 
 
 
binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. 
Virol. 69, 3584–3596 
8.  Buratti, E., Dörk, T., Zuccato, E., Pagani, F., Romano, M., and Baralle, F. E. 
(2001) Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo 
CFTR exon 9 skipping. EMBO J. 20, 1774–1784 
9.  Buratti, E., Brindisi, A., Pagani, F., and Baralle, F. E. (2004) Nuclear Factor 
TDP-43 Binds to the Polymorphic TG Repeats in CFTR Intron 8 and Causes 
Skipping of Exon 9: A Functional Link with Disease Penetrance. Am. J. Hum. 
Genet. 74, 1322–1325 
10.  Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, 
J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., Woltjer, R., 
Lopez, O. L., Hamilton, R., Tsuang, D. W., Galasko, D., Masliah, E., Kaye, J., 
Clark, C. M., Montine, T. J., Lee, V. M.-Y., and Trojanowski, J. Q. (2007) Co-
morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta 
Neuropathol. (Berl.). 114, 221–229 
11.  Arai, T., Mackenzie, I. R. A., Hasegawa, M., Nonoka, T., Niizato, K., Tsuchiya, 
K., Iritani, S., Onaya, M., and Akiyama, H. (2009) Phosphorylated TDP-43 in 
Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 
(Berl.). 117, 125–136 
12.  Walker, A. K., Daniels, C. M. L., Goldman, J. E., Trojanowski, J. Q., Lee, V. 
M.-Y., and Messing, A. (2014) Astrocytic TDP-43 Pathology in Alexander 
Disease. J. Neurosci. 34, 6448–6458 
13.  Wang, H.-Y., Wang, I.-F., Bose, J., and Shen, C.-K. J. (2004) Structural 
diversity and functional implications of the eukaryotic TDP gene family. 
Genomics. 83, 130–139 
14.  He, Y., and Smith, R. (2008) Nuclear functions of heterogeneous nuclear 
ribonucleoproteins A/B. Cell. Mol. Life Sci. 66, 1239–1256 
15.  Jean-Philippe, J., Paz, S., and Caputi, M. (2013) hnRNP A1: The Swiss Army 
Knife of Gene Expression. Int. J. Mol. Sci. 14, 18999–19024 
16.  Ayala, Y. M., Pantano, S., D’Ambrogio, A., Buratti, E., Brindisi, A., Marchetti, 
C., Romano, M., and Baralle, F. E. (2005) Human, Drosophila, and C.elegans 
106 
 
 
TDP43: nucleic acid binding properties and splicing regulatory function. J. 
Mol. Biol. 348, 575–588 
17.  Consortium, T. U. (2015) UniProt: a hub for protein information. Nucleic Acids 
Res. 43, D204–D212 
18.  Strong, M. J., Volkening, K., Hammond, R., Yang, W., Strong, W., Leystra-
Lantz, C., and Shoesmith, C. (2007) TDP43 is a human low molecular weight 
neurofilament (hNFL) mRNA-binding protein. Mol. Cell. Neurosci. 35, 320–
327 
19.  Buratti, E., and Baralle, F. E. (2012) TDP-43: gumming up neurons through 
protein-protein and protein-RNA interactions. Trends Biochem. Sci. 37, 237–
247 
20.  Buratti, E., and Baralle, F. E. (2001) Characterization and functional 
implications of the RNA binding properties of nuclear factor TDP-43, a novel 
splicing regulator of CFTR exon 9. J. Biol. Chem. 276, 36337–36343 
21.  Neumann, M., Kwong, L. K., Lee, E. B., Kremmer, E., Flatley, A., Xu, Y., 
Forman, M. S., Troost, D., Kretzschmar, H. A., Trojanowski, J. Q., and Lee, 
V. M.-Y. (2009) Phosphorylation of S409/410 of TDP-43 is a consistent 
feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta 
Neuropathol. (Berl.). 117, 137–149 
22.  Igaz, L. M., Kwong, L. K., Chen-Plotkin, A., Winton, M. J., Unger, T. L., Xu, 
Y., Neumann, M., Trojanowski, J. Q., and Lee, V. M.-Y. (2009) Expression of 
TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of 
TDP-43 Proteinopathies. J. Biol. Chem. 284, 8516–8524 
23.  Arai, T., Hasegawa, M., Nonoka, T., Kametani, F., Yamashita, M., Hosokawa, 
M., Niizato, K., Tsuchiya, K., Kobayashi, Z., Ikeda, K., Yoshida, M., Onaya, 
M., Fujishiro, H., and Akiyama, H. (2010) Phosphorylated and cleaved TDP-
43 in ALS, FTLD and other neurodegenerative disorders and in cellular 
models of TDP-43 proteinopathy. Neuropathology. 30, 170–181 
24.  Fuentealba, R. A., Udan, M., Bell, S., Wegorzewska, I., Shao, J., Diamond, 
M. I., Weihl, C. C., and Baloh, R. H. (2010) Interaction with Polyglutamine 
107 
 
 
Aggregates Reveals a Q/N-rich Domain in TDP-43. J. Biol. Chem. 285, 
26304–26314 
25.  Liachko, N. F., Guthrie, C. R., and Kraemer, B. C. (2010) Phosphorylation 
promotes neurotoxicity in a C. elegans model of TDP-43 proteinopathy. J. 
Neurosci. Off. J. Soc. Neurosci. 30, 16208–16219 
26.  Che, M.-X., Jiang, Y.-J., Xie, Y.-Y., Jiang, L.-L., and Hu, H.-Y. (2011) 
Aggregation of the 35-kDa fragment of TDP-43 causes formation of 
cytoplasmic inclusions and alteration of RNA processing. FASEB J. Off. Publ. 
Fed. Am. Soc. Exp. Biol. 25, 2344–2353 
27.  Miguel, L., Frébourg, T., Campion, D., and Lecourtois, M. (2011) Both 
cytoplasmic and nuclear accumulations of the protein are neurotoxic in 
Drosophila models of TDP-43 proteinopathies. Neurobiol. Dis. 41, 398–406 
28.  Yang, C., Wang, H., Qiao, T., Yang, B., Aliaga, L., Qiu, L., Tan, W., Salameh, 
J., McKenna-Yasek, D. M., Smith, T., Peng, L., Moore, M. J., Brown, R. H., 
Cai, H., and Xu, Z. (2014) Partial loss of TDP-43 function causes phenotypes 
of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 111, E1121–
1129 
29.  Buratti, E., and Baralle, F. E. (2008) Multiple roles of TDP-43 in gene 
expression, splicing regulation, and human disease. Front. Biosci. J. Virtual 
Libr. 13, 867–878 
30.  Freibaum, B. D., Chitta, R., High, A. A., and Taylor, J. P. (2010) Global 
analysis of TDP-43 interacting proteins reveals strong association with RNA 
splicing and translation machinery. J. Proteome Res. 9, 1104–1120 
31.  Winton, M. J., Igaz, L. M., Wong, M. M., Kwong, L. K., Trojanowski, J. Q., and 
Lee, V. M.-Y. (2008) Disturbance of Nuclear and Cytoplasmic TAR DNA-
binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, 
and Aggregate Formation. J. Biol. Chem. 283, 13302–13309 
32.  Passoni, M., De Conti, L., Baralle, M., and Buratti, E. (2012) UG 
Repeats/TDP-43 Interactions near 5′ Splice Sites Exert Unpredictable Effects 
on Splicing Modulation. J. Mol. Biol. 415, 46–60 
108 
 
 
33.  Buratti, E., Brindisi, A., Giombi, M., Tisminetzky, S., Ayala, Y. M., and Baralle, 
F. E. (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B 
through its C-terminal tail: an important region for the inhibition of cystic 
fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 
280, 37572–37584 
34.  Romano, M., Buratti, E., Romano, G., Klima, R., Del Bel Belluz, L., Stuani, C., 
Baralle, F., and Feiguin, F. (2014) Evolutionarily conserved heterogeneous 
nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with 
human and Drosophila TAR DNA-binding protein 43 (TDP-43). J. Biol. Chem. 
289, 7121–7130 
35.  Budini, M., Romano, V., Quadri, Z., Buratti, E., and Baralle, F. E. (2014) TDP-
43 loss of cellular function through aggregation requires additional structural 
determinants beyond its C-terminal Q/N prion-like domain. Hum. Mol. Genet. 
10.1093/hmg/ddu415 
36.  Volkening, K., Leystra-Lantz, C., Yang, W., Jaffee, H., and Strong, M. J. 
(2009) Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and 
copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA 
stability. Implications for altered RNA processing in amyotrophic lateral 
sclerosis (ALS). Brain Res. 1305, 168–182 
37.  Fiesel, F. C., Voigt, A., Weber, S. S., Van den Haute, C., Waldenmaier, A., 
Görner, K., Walter, M., Anderson, M. L., Kern, J. V., Rasse, T. M., Schmidt, 
T., Springer, W., Kirchner, R., Bonin, M., Neumann, M., Baekelandt, V., 
Alunni-Fabbroni, M., Schulz, J. B., and Kahle, P. J. (2010) Knockdown of 
transactive response DNA-binding protein (TDP-43) downregulates histone 
deacetylase 6. EMBO J. 29, 209–221 
38.  Bose, J. K., Huang, C.-C., and Shen, C.-K. J. (2011) Regulation of autophagy 
by neuropathological protein TDP-43. J. Biol. Chem. 286, 44441–44448 
39.  Ayala, Y. M., Misteli, T., and Baralle, F. E. (2008) TDP-43 regulates 
retinoblastoma protein phosphorylation through the repression of cyclin-
dependent kinase 6 expression. Proc. Natl. Acad. Sci. 105, 3785–3789 
109 
 
 
40.  Ayala, Y. M., De Conti, L., Avendaño-Vázquez, S. E., Dhir, A., Romano, M., 
D’Ambrogio, A., Tollervey, J., Ule, J., Baralle, M., Buratti, E., and Baralle, F. 
E. (2011) TDP-43 regulates its mRNA levels through a negative feedback 
loop. EMBO J. 30, 277–288 
41.  Buratti, E., De Conti, L., Stuani, C., Romano, M., Baralle, M., and Baralle, F. 
(2010) Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 
277, 2268–2281 
42.  Kawahara, Y., and Mieda-Sato, A. (2012) TDP-43 promotes microRNA 
biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. 
Acad. Sci. U. S. A. 109, 3347–3352 
43.  Dewey, C. M., Cenik, B., Sephton, C. F., Dries, D. R., Mayer, P., Good, S. K., 
Johnson, B. A., Herz, J., and Yu, G. (2011) TDP-43 is directed to stress 
granules by sorbitol, a novel physiological osmotic and oxidative stressor. 
Mol. Cell. Biol. 31, 1098–1108 
44.  McDonald, K. K., Aulas, A., Destroismaisons, L., Pickles, S., Beleac, E., 
Camu, W., Rouleau, G. A., and Velde, C. V. (2011) TAR DNA-Binding Protein 
43 (TDP-43) Regulates Stress Granule Dynamics via Differential Regulation 
of G3BP and TIA-1. Hum. Mol. Genet. 10.1093/hmg/ddr021 
45.  Zhang, T., Baldie, G., Periz, G., and Wang, J. (2014) RNA-Processing Protein 
TDP-43 Regulates FOXO-Dependent Protein Quality Control in Stress 
Response. PLoS Genet. 10, e1004693 
46.  Stoica, R., De Vos, K. J., Paillusson, S., Mueller, S., Sancho, R. M., Lau, K.-
F., Vizcay-Barrena, G., Lin, W.-L., Xu, Y.-F., Lewis, J., Dickson, D. W., 
Petrucelli, L., Mitchell, J. C., Shaw, C. E., and Miller, C. C. J. (2014) ER–
mitochondria associations are regulated by the VAPB–PTPIP51 interaction 
and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun. 
10.1038/ncomms4996 
47.  Ayala, Y. M., Zago, P., D’Ambrogio, A., Xu, Y.-F., Petrucelli, L., Buratti, E., 
and Baralle, F. E. (2008) Structural determinants of the cellular localization 
and shuttling of TDP-43. J. Cell Sci. 121, 3778–3785 
110 
 
 
48.  Zhang, Y.-J., Caulfield, T., Xu, Y.-F., Gendron, T. F., Hubbard, J., Stetler, C., 
Sasaguri, H., Whitelaw, E. C., Cai, S., Lee, W. C., and Petrucelli, L. (2013) 
The dual functions of the extreme N-terminus of TDP-43 in regulating its 
biological activity and inclusion formation. Hum. Mol. Genet. 22, 3112–3122 
49.  Yachdav, G., Kloppmann, E., Kajan, L., Hecht, M., Goldberg, T., Hamp, T., 
Hönigschmid, P., Schafferhans, A., Roos, M., Bernhofer, M., Richter, L., 
Ashkenazy, H., Punta, M., Schlessinger, A., Bromberg, Y., Schneider, R., 
Vriend, G., Sander, C., Ben-Tal, N., and Rost, B. (2014) PredictProtein--an 
open resource for online prediction of protein structural and functional 
features. Nucleic Acids Res. 42, W337–343 
50.  Chang, C., Wu, T.-H., Wu, C.-Y., Chiang, M., Toh, E. K.-W., Hsu, Y.-C., Lin, 
K.-F., Liao, Y., Huang, T., and Huang, J. J.-T. (2012) The N-terminus of TDP-
43 promotes its oligomerization and enhances DNA binding affinity. Biochem. 
Biophys. Res. Commun. 425, 219–224 
51.  Qin, H., Lim, L.-Z., Wei, Y., and Song, J. (2014) TDP-43 N terminus encodes 
a novel ubiquitin-like fold and its unfolded form in equilibrium that can be 
shifted by binding to ssDNA. Proc. Natl. Acad. Sci. U. S. A. 111, 18619–18624 
52.  Shiina, Y., Arima, K., Tabunoki, H., and Satoh, J. (2010) TDP-43 Dimerizes 
in Human Cells in Culture. Cell. Mol. Neurobiol. 30, 641–652 
53.  Zhang, Y.-J., Xu, Y.-F., Cook, C., Gendron, T. F., Roettges, P., Link, C. D., 
Lin, W.-L., Tong, J., Castanedes-Casey, M., Ash, P., Gass, J., Rangachari, 
V., Buratti, E., Baralle, F., Golde, T. E., Dickson, D. W., and Petrucelli, L. 
(2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular 
toxicity. Proc. Natl. Acad. Sci. 106, 7607–7612 
54.  Maris, C., Dominguez, C., and Allain, F. H.-T. (2005) The RNA recognition 
motif, a plastic RNA-binding platform to regulate post-transcriptional gene 
expression. FEBS J. 272, 2118–2131 
55.  Mackness, B. C., Tran, M. T., McClain, S. P., Matthews, C. R., and Zitzewitz, 
J. A. (2014) Folding of the RNA Recognition Motif (RRM) Domains of the 
Amyotrophic Lateral Sclerosis (ALS)-linked Protein TDP-43 Reveals an 
Intermediate State. J. Biol. Chem. 289, 8264–8276 
111 
 
 
56.  Kuo, P.-H., Doudeva, L. G., Wang, Y.-T., Shen, C.-K. J., and Yuan, H. S. 
(2009) Structural insights into TDP-43 in nucleic-acid binding and domain 
interactions. Nucleic Acids Res. 37, 1799–1808 
57.  Lukavsky, P. J., Daujotyte, D., Tollervey, J. R., Ule, J., Stuani, C., Buratti, E., 
Baralle, F. E., Damberger, F. F., and Allain, F. H.-T. (2013) Molecular basis 
of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. 
Mol. Biol. 20, 1443–1449 
58.  Adam, S. A., Nakagawa, T., Swanson, M. S., Woodruff, T. K., and Dreyfuss, 
G. (1986) mRNA polyadenylate-binding protein: gene isolation and 
sequencing and identification of a ribonucleoprotein consensus sequence. 
Mol. Cell. Biol. 6, 2932–2943 
59.  Kuo, P.-H., Chiang, C.-H., Wang, Y.-T., Doudeva, L. G., and Yuan, H. S. 
(2014) The crystal structure of TDP-43 RRM1-DNA complex reveals the 
specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res. 42, 
4712–4722 
60.  Bhardwaj, A., Myers, M. P., Buratti, E., and Baralle, F. E. (2013) 
Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res. 
41, 5062–5074 
61.  Ward, J. J., McGuffin, L. J., Bryson, K., Buxton, B. F., and Jones, D. T. (2004) 
The DISOPRED server for the prediction of protein disorder. Bioinformatics. 
20, 2138–2139 
62.  Xue, B., Dunbrack, R. L., Williams, R. W., Dunker, A. K., and Uversky, V. N. 
(2010) PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. 
Biochim. Biophys. Acta. 1804, 996–1010 
63.  Jiang, L.-L., Che, M.-X., Zhao, J., Zhou, C.-J., Xie, M.-Y., Li, H.-Y., He, J.-H., 
and Hu, H.-Y. (2013) Structural Transformation of the Amyloidogenic Core 
Region of TDP-43 Protein Initiates Its Aggregation and Cytoplasmic Inclusion. 
J. Biol. Chem. 288, 19614–19624 
64.  Budini, M., Buratti, E., Stuani, C., Guarnaccia, C., Romano, V., De Conti, L., 
and Baralle, F. E. (2012) Cellular model of TAR DNA-binding protein 43 (TDP-
112 
 
 
43) aggregation based on its C-terminal Gln/Asn-rich region. J. Biol. Chem. 
287, 7512–7525 
65.  D’Ambrogio, A., Buratti, E., Stuani, C., Guarnaccia, C., Romano, M., Ayala, 
Y. M., and Baralle, F. E. (2009) Functional mapping of the interaction between 
TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 37, 4116–4126 
66.  Taylor, J. P., Tanaka, F., Robitschek, J., Sandoval, C. M., Taye, A., Markovic-
Plese, S., and Fischbeck, K. H. (2003) Aggresomes protect cells by 
enhancing the degradation of toxic polyglutamine-containing protein. Hum. 
Mol. Genet. 12, 749–757 
67.  Chiti, F., and Dobson, C. M. (2006) Protein Misfolding, Functional Amyloid, 
and Human Disease. Annu. Rev. Biochem. 75, 333–366 
68.  Mompeán, M., Buratti, E., Guarnaccia, C., Brito, R. M. M., Chakrabartty, A., 
Baralle, F. E., and Laurents, D. V. (2014) Structural characterization of the 
minimal segment of TDP-43 competent for aggregation. Arch. Biochem. 
Biophys. 545, 53–62 
69.  Wang, I.-F., Chang, H.-Y., Hou, S.-C., Liou, G.-G., Way, T.-D., and James 
Shen, C.-K. (2012) The self-interaction of native TDP-43 C terminus inhibits 
its degradation and contributes to early proteinopathies. Nat. Commun. 3, 766 
70.  Da Cruz, S., and Cleveland, D. W. (2011) Understanding the role of TDP-43 
and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 21, 904–919 
71.  Nehls, J., Koppensteiner, H., Brack-Werner, R., Floss, T., and Schindler, M. 
(2014) HIV-1 replication in human immune cells is independent of TAR DNA 
binding protein 43 (TDP-43) expression. PloS One. 9, e105478 
72.  Ayala, Y. M., Pagani, F., and Baralle, F. E. (2006) TDP43 depletion rescues 
aberrant CFTR exon 9 skipping. FEBS Lett. 580, 1339–1344 
73.  Zhang, Y.-J., Xu, Y., Dickey, C. A., Buratti, E., Baralle, F., Bailey, R., 
Pickering-Brown, S., Dickson, D., and Petrucelli, L. (2007) Progranulin 
mediates caspase-dependent cleavage of TAR DNA binding protein-43. J. 
Neurosci. Off. J. Soc. Neurosci. 27, 10530–10534 
74.  De Marco, G., Lomartire, A., Mandili, G., Lupino, E., Buccinnà, B., 
Ramondetti, C., Moglia, C., Novelli, F., Piccinini, M., Mostert, M., Rinaudo, M. 
113 
 
 
T., Chiò, A., and Calvo, A. (2014) Reduced cellular Ca2+ availability enhances 
TDP-43 cleavage by apoptotic caspases. Biochim. Biophys. Acta BBA - Mol. 
Cell Res. 1843, 725–734 
75.  Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, 
N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. 
F., Ivnik, R. J., Smith, G. E., Jr, C. R. J., Parisi, J. E., Petersen, R. C., and 
Dickson, D. W. (2014) TDP-43 is a key player in the clinical features 
associated with Alzheimer’s disease. Acta Neuropathol. (Berl.). 127, 811–824 
76.  Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., 
Vande Velde, C., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, 
F., Pradat, P.-F., Camu, W., Meininger, V., Dupre, N., and Rouleau, G. A. 
(2008) TARDBP mutations in individuals with sporadic and familial 
amyotrophic lateral sclerosis. Nat. Genet. 40, 572–574 
77.  Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., 
Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., Baralle, F., de 
Belleroche, J., Mitchell, J. D., Leigh, P. N., Al-Chalabi, A., Miller, C. C., 
Nicholson, G., and Shaw, C. E. (2008) TDP-43 mutations in familial and 
sporadic amyotrophic lateral sclerosis. Science. 319, 1668–1672 
78.  Corrado, L., Ratti, A., Gellera, C., Buratti, E., Castellotti, B., Carlomagno, Y., 
Ticozzi, N., Mazzini, L., Testa, L., Taroni, F., Baralle, F. E., Silani, V., and 
D’Alfonso, S. (2009) High frequency of TARDBP gene mutations in Italian 
patients with amyotrophic lateral sclerosis. Hum. Mutat. 30, 688–694 
79.  Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, 
Y., Beach, T. G., Buratti, E., Baralle, F., Morita, M., Nakano, I., Oda, T., 
Tsuchiya, K., and Akiyama, H. (2008) Phosphorylated TDP-43 in 
frontotemporal lobar degeneration and ALS. Ann. Neurol. 64, 60–70 
80.  Kametani, F., Nonaka, T., Suzuki, T., Arai, T., Dohmae, N., Akiyama, H., and 
Hasegawa, M. (2009) Identification of casein kinase-1 phosphorylation sites 
on TDP-43. Biochem. Biophys. Res. Commun. 382, 405–409 
114 
 
 
81.  Liachko, N. F., McMillan, P. J., Guthrie, C. R., Bird, T. D., Leverenz, J. B., and 
Kraemer, B. C. (2013) CDC7 inhibition blocks pathological TDP-43 
phosphorylation and neurodegeneration. Ann. Neurol. 74, 39–52 
82.  Inukai, Y., Nonaka, T., Arai, T., Yoshida, M., Hashizume, Y., Beach, T. G., 
Buratti, E., Baralle, F. E., Akiyama, H., Hisanaga, S., and Hasegawa, M. 
(2008) Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and 
ALS. FEBS Lett. 582, 2899–2904 
83.  Kim, K. Y., Lee, H.-W., Shim, Y., Mook-Jung, I., Jeon, G. S., and Sung, J.-J. 
(2015) A phosphomimetic mutant TDP-43 (S409/410E) induces Drosha 
instability and cytotoxicity in Neuro 2A cells. Biochem. Biophys. Res. 
Commun. 464, 236–243 
84.  Zhang, Y.-J., Gendron, T. F., Xu, Y.-F., Ko, L.-W., Yen, S.-H., and Petrucelli, 
L. (2010) Phosphorylation regulates proteasomal-mediated degradation and 
solubility of TAR DNA binding protein-43 C-terminal fragments. Mol. 
Neurodegener. 5, 33 
85.  Brady, O. A., Meng, P., Zheng, Y., Mao, Y., and Hu, F. (2011) Regulation of 
TDP-43 aggregation by phosphorylation and p62/SQSTM1. J. Neurochem. 
116, 248–259 
86.  Li, H.-Y., Yeh, P.-A., Chiu, H.-C., Tang, C.-Y., and Tu, B. P. (2011) 
Hyperphosphorylation as a Defense Mechanism to Reduce TDP-43 
Aggregation. PLoS ONE. 10.1371/journal.pone.0023075 
87.  Dormann, D., Capell, A., Carlson, A. M., Shankaran, S. S., Rodde, R., 
Neumann, M., Kremmer, E., Matsuwaki, T., Yamanouchi, K., Nishihara, M., 
and Haass, C. (2009) Proteolytic processing of TAR DNA binding protein-43 
by caspases produces C-terminal fragments with disease defining properties 
independent of progranulin. J. Neurochem. 110, 1082–1094 
88.  Liu, Y., Duan, W., Guo, Y., Li, Z., Han, H., Zhang, S., Yuan, P., and Li, C. 
(2014) A new cellular model of pathological TDP-43: The neurotoxicity of 
stably expressed CTF25 of TDP-43 depends on the proteasome. 
Neuroscience. 281C, 88–98 
115 
 
 
89.  Nonaka, T., Arai, T., Buratti, E., Baralle, F. E., Akiyama, H., and Hasegawa, 
M. (2009) Phosphorylated and ubiquitinated TDP-43 pathological inclusions 
in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett. 583, 394–
400 
90.  Tompa, P. (2002) Intrinsically unstructured proteins. Trends Biochem. Sci. 27, 
527–533 
91.  Uversky, V. N. (2013) The most important thing is the tail: Multitudinous 
functionalities of intrinsically disordered protein termini. FEBS Lett. 587, 
1891–1901 
92.  Pufall, M. A., and Graves, B. J. (2002) Autoinhibitory domains: modular 
effectors of cellular regulation. Annu. Rev. Cell Dev. Biol. 18, 421–462 
93.  Trudeau, T., Nassar, R., Cumberworth, A., Wong, E. T. C., Woollard, G., and 
Gsponer, J. (2013) Structure and Intrinsic Disorder in Protein Autoinhibition. 
Structure. 21, 332–341 
94.  Jayaraman, B., and Nicholson, L. K. (2007) Thermodynamic Dissection of the 
Ezrin FERM/CERMAD Interface†. Biochemistry (Mosc.). 46, 12174–12189 
95.  Christie, D. A., Lemke, C. D., Elias, I. M., Chau, L. A., Kirchhof, M. G., Li, B., 
Ball, E. H., Dunn, S. D., Hatch, G. M., and Madrenas, J. (2011) Stomatin-Like 
Protein 2 Binds Cardiolipin and Regulates Mitochondrial Biogenesis and 
Function. Mol. Cell. Biol. 31, 3845–3856 
96.  Schӓgger, H. (2006) Tricine-SDS-PAGE : Nature Protocols. Nat Protoc. 1, 
16–22 
97.  Chung, C. (2014) Structure and Interactions of the C-terminal Domain of TDP-
43. Honors Biochem. Thesis 
98.  Vasanthakumar, T. (2014) Characterization of the C-terminal domain of TDP-
43. Honors Biochem. Thesis 
99.  Dunn, S. D. (1986) Effects of the modification of transfer buffer composition 
and the renaturation of proteins in gels on the recognition of proteins on 
western blots by monoclonal antibodies. Anal. Biochem. 157, 144–153 
100.  Walker, J. M. (ed.) (1996) The Iodogen Method for Radiolabeling Protein - 
Springer, Humana Press, [online] 
116 
 
 
http://link.springer.com/protocol/10.1007%2F978-1-60327-259-9_115 
(Accessed August 20, 2015) 
101.  Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J., and Schubert, 
D. (2002) Size-distribution analysis of proteins by analytical 
ultracentrifugation: strategies and application to model systems. Biophys. J. 
82, 1096–1111 
102.  Baynes, B. M., Wang, D. I. C., and Trout, B. L. (2005) Role of Arginine in 
the Stabilization of Proteins against Aggregation†. Biochemistry (Mosc.). 44, 
4919–4925 
103.  Jao, S.-C., Ma, K., Talafous, J., Orlando, R., and Zagorski, M. G. (1997) 
Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-
peptide. Amyloid. 4, 240–252 
104.  Jadwin, J. A., Mayer, B. J., and Machida, K. (2015) Detection and 
quantification of protein-protein interactions by far-Western blotting. Methods 
Mol. Biol. Clifton NJ. 1312, 379–398 
105.  Bondos, S. E., and Bicknell, A. (2003) Detection and prevention of protein 
aggregation before, during, and after purification. Anal. Biochem. 316, 223–
231 
106.  Dam, J., and Schuck, P. (2005) Sedimentation Velocity Analysis of 
Heterogeneous Protein-Protein Interactions: Sedimentation Coefficient 
Distributions c(s) and Asymptotic Boundary Profiles from Gilbert-Jenkins 
Theory. Biophys. J. 89, 651–666 
107.  Dogan, J., Gianni, S., and Jemth, P. (2014) The binding mechanisms of 
intrinsically disordered proteins. Phys. Chem. Chem. Phys. 16, 6323–6331 
108.  Arthur, K. K., Gabrielson, J. P., Kendrick, B. S., and Stoner, M. R. (2009) 
Detection of protein aggregates by sedimentation velocity analytical 
ultracentrifugation (SV-AUC): Sources of variability and their relative 
importance. J. Pharm. Sci. 98, 3522–3539 
109.  Boulikas, T. (1992) Nuclear localization signals (NLS). Crit. Rev. Eukaryot. 
Gene Expr. 3, 193–227 
117 
 
 
110.  Fuentealba, R. A., Udan, M., Bell, S., Wegorzewska, I., Shao, J., Diamond, 
M. I., Weihl, C. C., and Baloh, R. H. (2010) Interaction with Polyglutamine 
Aggregates Reveals a Q/N-rich Domain in TDP-43. J. Biol. Chem. 285, 
26304–26314 
111.  Weihl, C. C., Temiz, P., Miller, S. E., Watts, G., Smith, C., Forman, M., 
Hanson, P. I., Kimonis, V., and Pestronk, A. (2008) TDP-43 accumulation in 
inclusion body myopathy muscle suggests a common pathogenic mechanism 
with frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 79, 1186–
1189 
118 
 
 
Curriculum Vitae 
Post-Secondary Education 
 
2013-2015    Master of Science Candidate, Biochemistry 
The University of Western Ontario, London, Ontario, Canada 
Title: “Interdomain interactions of the transactive response DNA binding 
protein 43 kDa (TDP-43)” 
Co-supervisors: Dr. Stanley D. Dunn and Dr. Michael J. Strong 
 
 
2008-2013    Honors Specialization in Clinical Biochemistry 
Bachelor of Medical Science 
The University of Western Ontario, London, Ontario, Canada 
 
 
Scholarships and Awards 
 
2013-2015    Western Graduate Research Scholarship 
 Awarded to eligible full-time graduate students 
 
2014              Third Place Poster Presenter, ALS Society of Canada 10th Annual 
Research Forum, Toronto, Ontario 
 Poster entitled: “Inter-domain interactions of the RNA-binding 
protein, TDP-43” 
 Awarded based on a judging panel 
 
2013              First Place Poster Presenter, Fourth International Research Workshop 
on Frontotemporal Dementia in ALS 
 Poster entitled: “Inter-domain interactions of the RNA-binding 
protein, TDP-43” 
 Awarded based on a judging panel 
 
2008              Western Scholarship of Excellence 
 Awarded for achieving an above 90% average in final year of 
secondary school 
 
  
119 
 
 
Research Experience 
 
2013-2015    Research-based Master’s Thesis, Department of Biochemistry 
The University of Western Ontario, London, ON, Canada 
Co-supervisors: Dr. Stanley D. Dunn and Dr. Michael J. Strong 
 Identified an interaction between two domains of the protein TDP-43 
 Studied protein interactions through biophysical techniques including 
analytical ultracentrifugation and Far Western blotting 
 Helped with planning colocalization studies  
 Purified recombinant proteins via column chromatography 
 Planned and cloned various TDP-43 expression plasmids through 
molecular biology techniques 
 Prepared presentations/posters of my research for meetings and 
conferences 
 
2012-2013    Honors Undergraduate Thesis, Department of Biochemistry 
The University of Western Ontario, London, ON, Canada 
Supervisor: Dr. Stanley D. Dunn 
 Found preliminary evidence for an interaction between two domains 
of TDP-43 
 Planned and cloned various TDP-43 expression plasmids through 
molecular biology techniques 
 Purified recombinant proteins via column chromatography 
 Wrote a final thesis report 
 Prepared presentations and a poster for symposia within the 
department 
 
2011-2012    Science Internship Program, LANXESS Inc., London ON, Canada 
 Worked in Product Research Group, on TPV Team 
 Planned and conducted lab experiments modifying butyl rubber 
 Analyzed results using IR, NMR, titration and other rubber industry 
equipment 
 Wrote multiple technical reports detailing work performed, result 
analysis and future recommendations 
 Took part in weekly team meetings, preparing presentations detailing 
resent results and paths forward 
  
120 
 
 
Presentations and Abstracts 
 
2015             Poster and Podium Presentation, Fifth International Research Workshop 
on Frontotemporal Dementia in ALS, London, Ontario, Canada 
 Title: Inter-domain interactions of the RNA-binding protein, TDP-43 
 Authors: Karen Dunkerley1, Yumin Bi1, Kathryn Volkening2,3, 
Michael J. Strong2,3 and Stanley D. Dunn1 
 
2015             Poster Presentation and Abstract Submission, London Health 
Research Day 2015, London, Ontario, Canada 
 Title: Inter-domain interactions of the RNA-binding protein, TDP-43 
 Authors: Karen Dunkerley, Yumin Bi, Kathryn Volkening, Michael J. 
Strong and Stanley D. Dunn 
 
2015             Presentation, Graduate Student Seminars, Department of Biochemistry 
 Title: Characterization of interdomain interactions in the RNA-
binding protein, TDP-43 
 Author: Karen Dunkerley 
 
2014             Poster Presentation, ALS Society of Canada 10th Annual Research 
Forum, Toronto, Ontario 
 Title: Inter-domain interactions of the RNA-binding protein, TDP-43 
 Authors: Karen Dunkerley, Yumin Bi, Kathryn Volkening, Michael J. 
Strong and Stanley D. Dunn 
 
2014             Poster Presentation and Abstract Submission, London Health 
Research Day 2014, London, Ontario, Canada 
 Title: Inter-domain interactions of the RNA-binding protein, TDP-43 
 Authors: Karen Dunkerley, Yumin Bi, Kathryn Volkening, Michael J. 
Strong and Stanley D. Dunn 
 
2013             Poster and Podium Presentation, Fourth International Research 
Workshop on Frontotemporal Dementia in ALS, London, Ontario, Canada 
 Title: Characterization of TDP-43 Domain Interactions 
 Authors: Karen Dunkerley, Yumin Bi, Kathryn Volkening, Michael J. 
Strong and Stanley D. Dunn 
 
2013             Poster Presentation, Harold B. Stewart Memorial Lecture and Research 
Showcase, London, Ontario, Canada 
 Title: Characterization of TDP-43 Domain Interactions 
121 
 
 
 Authors: Karen Dunkerley, Yumin Bi and Stanley D. Dunn 
 
Teaching Experience 
 
2013-2014    Teaching Assistant, Department of Biochemistry, The University of 
Western Ontario, London, Ontario, Canada  
Courses: Biochemistry 3381A, 4420A 
 Planned and conducted tutorials 
 Held office hours 
 Graded student assignments and exams 
 Proctored exams 
 Reported student progress/concerns to course instructors 
 
